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EFFECTS OF IMMUNOLOGICAL TARGETING OF TWO MOSQUITO ANTIGENS 
AND ORAL INGESTION OF ANTHELMINTIC DRUGS ON THE YELLOW FEVER 
MOSQUITO, AEDES AEGYPTI (DIPTERA: CULICIDAE) 
Aedes aegypti is one of the most important mosquito vectors of human 
arboviruses, including dengue viruses, chikungunya virus, and yellow fever virus.   
Human infection with these viruses constitutes an enormous global disease burden.  
Current control methods rely heavily on the use of insecticides, which are rapidly losing 
their utility due to the spread of insecticide resistance.  Anti-vector vaccines and 
anthelmintic drugs with insecticidal properties have been proposed as novel means to 
decrease pathogen transmission by reducing the daily probability of mosquito survival.  
The aims of this dissertation research were to: evaluate the Ae. aegypti mosquito 
lysosomal aspartic protease and the glutamate-gated chloride anion channel as potential 
mosquitocidal antigens, evaluate drugs frequently used in mass drug administration 
campaigns for their ability to induce a mosquitocidal effect when imbibed in a blood 
meal, to assess the variation in susceptibility of Ae. aegypti strains to orally imbibed 
ivermectin, and finally to determine if resistance to ivermectin could be selected for in a 
genetically diverse laboratory strain of Ae. aegypti.  Despite the utilization of several 
immunization regimens, a specific mosquitocidal immune response against the Ae. 
aegypti mosquito lysosomal aspartic protease could not be verified. In vitro experiments 




failed to elicit a mosquitocidal response, suggesting that it is an unlikely mosquitocidal 
antigen.  In vitro blood feeding experiments with several anthelmintic drugs revealed that 
high concentrations of macrocyclic lactones (including ivermectin, selamectin and 
moxidectin) were effective in reducing adult mosquito survival and that sublethal 
concentrations resulted in reduced fecundity and egg hatch rate.  When imbibed in a 
blood meal, diethylcarbamazine, albendazole-sulfoxide and pyrantel pamoate, which are 
all currently used in human mass drug administration campaigns for controlling parasitic 
pathogens in humans, had no effect on adult mosquito survival.  Significant differences in 
susceptibility to ivermectin, according to mosquito strain, were observed, with three 
permethrin-resistant strains of Ae. aegypti being the most refractory to ivermectin, 
suggesting a possible permethrin-induced cross resistance mechanism to ivermectin.  
After subjecting a genetically diverse laboratory strain of Ae. aegypti to three successive 
rounds of selection with orally imbibed ivermectin, no resistance to the drug was 
apparent.   Although mass drug administration is unlikely to have any impact on the 
transmission of Ae. aegypti vectored pathogens, Ae. aegypti  may prove to be a useful 
model for studying the effects of ivermectin in the mosquito, including studying potential 
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 Aedes aegypti is a container-breeding mosquito in the subgenus Stegomyia which 
is globally distributed throughout the tropics and subtropics.  There are at least two 
subspecies of Ae. aegypti, which include Ae. aegypti aegypti and Ae. aegypti formosus.  
The subspecies Ae. aegypti formosus occurs in sub-Saharan Africa, and preferentially 
oviposits in treeholes, and is rarely associated with urban arbovirus epidemics.  The 
subspecies Ae. aegypti aegypti is a synanthropic vector and preferentially oviposits in 
artificial containers such as tires or trash that have collected rain water.  Several 
characteristics, including extreme anthropophily (a preference to feed on human blood), a 
long life span and frequent blood feeding behavior make Ae. aegypti aegypti an 
exceptional vector for arboviruses of public health concern (Scott et al. 2000a, Harrington 
et al. 2001).  
The global burden of arboviruses transmitted by Ae. aegypti. 
 Female mosquitoes of most mosquito species, including Ae. aegypti, must imbibe 
a blood meal for egg maturation.  Aedes aegypti often takes multiple blood meals within a 
single gonadotropic cycle, thus making it a potent and deadly vector of arthropod-borne 
viruses (arboviruses).  Aedes aegypti is one of the most important vectors of human 
arboviruses, including dengue viruses (DENV), chikungunya virus (CHIKV) and yellow 
fever virus (YFV) (Gubler 2002, Staples et al. 2009).   
Dengue.  In the past few decades, the incidence of infection with various 
arboviruses has increased, but have not surpassed dengue viruses with respect to their 




and tropical areas of Southeast Asia, the Pacific, the Americas, the Eastern Mediterranean 
and in Africa are at risk of infection (WHO 2007).  Globally, it is estimated that dengue 
sickens 50-100 million people, killing an estimated 19,000 annually (Mackenzie et al. 
2004).  Of significant concern is the rise in the number of dengue fever (DF) and dengue 
hemorrhagic fever (DHF) cases reported to the World Health Organization, and the fact 
that the geographical areas in which dengue transmission occurs have expanded (Rigau-
Perez et al. 1998, Gubler and Meltzer 1999, Gubler 2004, Wilder-Smith and Schwartz 
2005, Guzman et al. 2010).  The number of cases reported between 2000-2004 nearly 
doubled from the number of cases recorded from 1990-1999 (WHO 2007).  Dengue 
epidemics are costly and impart a significant economic burden on areas affected.  The 
costs associated with a 1981 dengue epidemic were estimated at US$103 million (Kouri 
et al. 1989), and in endemic countries in the Americas and Asia, the burden of dengue is 
approximately 1,300 disability-adjusted life years (DALYs) per million population; a 
number on the same magnitude as malaria and meningitis (Gubler and Meltzer 1999, 
Clark et al. 2005). 
   Dengue fever (DF), sometimes referred to as “breakbone fever,” is caused by 
infection with a dengue virus (DENV).  There are four dengue virus serotypes, referred to 
as DENV-1, DENV-2, DENV-3 and DENV-4.  In most cases, DF is a self-limiting, 
febrile illness characterized by a high fever, headache, retroorbital pain, bone pain, and a 
rash (Monath and Heinz 1996).  Dengue hemorrhagic fever (DHF) and dengue shock 
syndrome (DSS) are more severe forms of disease resulting from DENV infection.  In the 
case of DHF/DSS, spontaneous hemorrhages can occur internally and externally, and 




leading to severe hypotension and shock (Monath and Heinz 1996).  Currently, there is 
neither a vaccine or an anti-viral therapy that is effective in preventing or treating 
infection with DENV, and treatment of DF, DHF and DSS rely on supportive therapies 
such as oral or intravenous fluids and acetaminophen  (Guzman et al. 2010).  
Dengue viruses circulate through three transmission cycles: the sylvatic, 
rural/epidemic and urban/epidemic transmission cycles (Gubler 1998).  In the sylvatic 
cycle, DENV is passed between susceptible monkey species and canopy-dwelling Aedes 
mosquitoes.  In the rural/epidemic transmission cycle, peridomestic mosquito vectors 
such as Aedes polynesiensis, Aedes albopictus, and possibly Aedes mediovittatus bridge 
the transmission of DENV from the enzootic transmission cycle to the human population.  
In the urban/epidemic cycle, DENV viruses are transmitted laterally between humans and 
the mosquito vector alone, with Ae. aegypti being the principle vector for epidemic 
dengue transmission.   
Chikungunya. Chikungunya fever is an acute febrile illness resulting from 
infection with CHIKV.  The word, Chikungunya, is derived from the Makonde word 
meaning, “that which bends up,” which references the characteristic stooped posture 
observed in individuals experiencing the sometimes debilitating arthritic symptoms 
resulting from infection with CHIKV (Robinson 1955).  While death due to infection 
with CHIKV is rarely observed, the arthralgia resulting from infection can be debilitating 
and can last from several weeks to months.  Like DEN viruses, CHIKV has been found to 
circulate in a sylvatic cycle between forest-dwelling Aedes mosquitoes and nonhuman 
primates (Jupp and McIntosh 1988).  Also similar to DEN viruses, the virus can be 




the two principle vectors being Ae. aegypti and Ae. albopictus.   In 2004, a major 
outbreak of CHIKV occurred.  The outbreak originated on the Kenyan coast, and spread 
rapidly throughout several islands in the Indian Ocean, Southeast Asia and India (Staples 
et al. 2009), and was imported into at least 18 countries throughout Asia, Europe, and 
North America where cases of chikungunya fever had previously been unreported (Rezza 
et al. 2007, Kariuki Njenga et al. 2008, Sergon et al. 2008). 
Yellow fever.  To date, only one arbovirus, the yellow fever virus, has a safe and 
effective vaccine for prevention of infection.  Despite the availability of the vaccine, 
yellow fever epidemics continue to occur in parts of Africa and South America, with 
mortality rates as high as 81 percent (Gould et al. 2008, Ekenna et al. 2010).  The 
epidemiology of yellow fever is quite similar to that of dengue, with the sylvatic cycle 
and urban epidemic cycles being bridged.   Yellow fever is caused by infection with the 
yellow fever virus, with Ae. aegypti being a frequent vector.  Indeed, Ae. aegypti is so 
often associated with yellow fever transmission that it is often referred to as the “yellow 
fever mosquito.”  
  Historical and current vector control strategies 
 In the 1950’s-1960s, under the organization of the Pan American Health 
Organization, many countries in South and Central America eradicated Ae. aegypti 
through the use of environmental management and insecticides (Gubler 1998).   
Regrettably, many of these programs were eliminated in the early 1970’s and shortly after 
their discontinuation Ae. aegypti re-infested the areas and dengue epidemics resurfaced.   
Increased urbanization, travel, and a lack of mosquito control measures have lead to the 




combined with the emergence of new virus strains and the importation of novel serotypes 
has lead to a sharp increase in the number of DF and DHF cases. 
 In recent years, there have been concerted efforts to encourage community 
participation in the control of Ae. aegypti, with emphasis being placed on educating 
community members of the importance of source (container) reductions (Winch et al. 
1991, Leontsini et al. 1993, Lloyd et al. 1994, Rosenbaum et al. 1995). While such 
programs and campaigns have and continue to be successful, they are difficult to 
maintain because of the fact that a sustained and consistent effort is required.  It is clear 
that integrated vector elimination efforts are the most effective at preventing epidemic 
outbreaks of arboviral disease in the human population; however, focus has shifted 
towards chemical control measures (Lloyd 2003).    
Ultra-low volume (ULV) aerosols are recommended for use primarily during an 
epidemic outbreak of an arboviral disease such as dengue.  However, the routine use of 
ULV application of insecticides is widespread (Gubler 2002).  The utility of aerosol 
insecticides is threatened by the spread of pyrethroid resistance, which has been reported 
in several locations across the globe (Flores et al. 2006, Jirakanjanakit et al. 2007b, 
Jirakanjanakit et al. 2007a).  
Vectorial capacity 
 It is clear from the eradication efforts from the 1950’s-1960’s that vector 
eradication efforts will, indeed, curb rural epidemic transmission cycles of arboviruses.  
However, it is also quite clear that such efforts may not be sustainable in the long term.  




area is ever present.  Likewise, as seen in the 2004 CHIKV epidemic, an arbovirus can 
enter a human population through importation and result in local autochthonous (or local) 
transmission (Powers and Logue 2007).   In the face of the rapid spread of insecticide 
resistance, it is clear that population suppression is neither a sustainable nor effective 
practice for reducing arboviral transmission.    
The Vectorial capacity (V) is the average number of potentially infective bites 
delivered by all of the vectors feeding on a single host in one day (Fine 1981, Black and 





Vectorial capacity takes into account many different aspects of pathogen transmission by 
an arthropod vector, including the vector density in relation to the host (m), the 
probability that a vector feeds on a host in one day (a), the proportion of vectors ingesting 
an infective meal that become infective (b), the probability that the vector will survive 
one day (p), the duration of the extrinsic incubation period (EIP), given in days, (n), and 
the duration of the vector’s life, in days, after surviving the extrinsic incubation period 
(1/-ln p).  Three variables, a, n and p are the variables that are the most influential on the 
magnitude of V.  However, small changes in p are the most influential on the magnitude 
of V.  The vectorial capacity model predicts that control strategies that may cause even 
slight reductions in the daily probability of mosquito survival can have a profound impact 
on pathogen transmission by a mosquito vector.  Ultimately, such a strategy would target 
the ability of a mosquito to survive the EIP.  If the vector fails to survive the EIP, it is 




approaches, mosquitocidal vaccines and oral ingestion of anthelmintic drugs in a blood 
meal, for their ability to shorten the life span of Ae. aegypti.  Importantly, the same 
characteristics that make Ae. aegypti such an efficient vector (extreme anthropophily, 
long life span and frequent blood-feeding behavior) are specifically targeted through 
either a mosquitocidal vaccine or through the ingestion of an anthelmintic drug 
circulating in the bloodstream of a human host.  Because urban epidemics of dengue, 
chikungunya, and Yellow Fever are transmitted laterally between humans and 
mosquitoes, the vaccine or anthelmintic drugs need only be administered to humans.  
Aedes aegypti is also a frequent feeder, and it is estimated that the mosquito will feed on 
five to ten humans over the course of the EIP (Scott et al. 2000a, Harrington et al. 2001).  
Only one blood meal needs to be mosquitocidal to interrupt disease transmission.  
Further, because the mosquito feeds frequently, coverage of the human population would 
not need to be complete.  Mathematical models have predicted that limited vaccine 
efficacy and coverage that causes only small reductions in the daily probability of 
mosquito survival can translate into drastic reductions in the transmission of dengue 
viruses (Billingsley et al. 2008).   Wilson (1993) also highlights the potential ability of 
orally imbibed endectocides to decrease vectorial capacity by interrupting the EIP, rather 
than through population suppression.   
Anti-vector vaccines 
  A historical account of anti-vector vaccines 
Anti-vector immunity was first demonstrated by William Trager in 1939.  Trager 
immunized guinea pigs and rabbits with extracts from the tick Dermacentor variabilis, 




exhibited reduced survival after blood feeding (Trager 1939b, a).   In the seven decades 
since Trager’s reports of anti-tick immunity, anti-vector research has been conducted 
with many arthropod vectors, but limited success has been achieved in identifying 
specific anti-vector antigens.   In the 72 years since Trager’s discovery, a handful of anti-
vector antigens have been described, and most of these are from ticks (Willadsen 2004).   
The development of anti-vector vaccines relies on priming a vertebrate immune 
system against vector antigens belonging to one of two groups: antigens to which the host 
is exposed during vector feeding, and “concealed” antigens which reside inside the vector 
to which the host immune system would be exposed during the host-vector interaction 
(Willadsen et al. 1993, Willadsen 2004).  Ultimately, the vector would imbibe immune 
components from the host which would prevent the vector from feeding or drastically 
reduce survival following a blood meal.  While anti-vector research has been conducted 
with many major arthropod vectors, anti-tick research has been the most successful, 
culminating in the development and deployment of two commercial anti-tick vaccines, 
both of which incorporate a recombinant glycoprotein (Bm86) from the cattle tick, 
Boophilus microplus, as the immunization antigen (Willadsen et al. 1995a, Garcia et al. 
2009).  The Bm86 antigen was identified by first immunizing cattle with crude extracts 
prepared from homogenates of B. microplus, and then subjecting immunized cattle to a 
tick bioassay (Johnston et al. 1986, Kemp et al. 1986).  Isolating the Bm86 antigen was 
laborious, requiring multiple rounds of biochemical fractionation and purification 
followed by immunizations and tick challenges, with the final purification of the Bm86 
protein requiring nearly one kilogram of engorged ticks (Willadsen et al. 1989).  




over 12 years to accomplish (Willadsen 2004), a remarkably short time frame when 
compared to the time required to develop and license pesticides or pharmaceuticals.   The 
two vaccine preparations, TickGARD Plus and GAVAC Plus have been used in Australia 
and South America, respectively, and are effective in reducing the tick burden of cattle 
(de la Fuente et al. 1998, de la Fuente et al. 1999, Jonsson et al. 2000, Valle et al. 2004).  
The success of developing and licensing TickGARD Plus and GAVAC Plus demonstrate 
that development and deployment of anti-vector vaccines is not only feasible, but may 
also require less time for development and deployment than traditional pesticides or 
pharmaceuticals.   
While the development and licensing of TickGARD Plus and GAVAC Plus are 
encouraging, progress in identifying other anti-vector antigens has been slow, and the 
majority of the described anti-vector antigens are from ticks.  Other vectors for which 
anti-vector antigens have been described include: the sheep blow fly, Lucilia cuprina, and 
the mosquitoes Anopheles gambiae and Aedes albopictus. Immunologic targeting of two 
peritrophic matrix proteins of  L. cuprina is effective in reducing survival of the larvae in 
vivo (Wijffels et al. 1999).  To date, only two specific mosquitocidal antigens, the 
Anopheles gambiae mucin I (AgMucI) and Aedes albopictus subolesin, have been 
described (Foy et al. 2003, Canales et al. 2009).   
Anti-mosquito immunity was first demonstrated by Alger and Cabrea (1972), who 
immunized rabbits with homogenate prepared from the midguts of Anopheles stephensi 
mosquitoes.  Since Alger and Cabrea’s report, a number of other studies demonstrating 
anti-mosquito immunity have been published (Alger and Cabrera 1972, Sutherland and 




1995, Ramasamy et al. 1996, Almeida and Billingsley 1998, Lal et al. 2001), but results 
from the reports are difficult to compare because of the disparate methodologies and 
immunization preparations used in the experiments.  Immunized animals included mice, 
guinea pigs and rabbits, and the methods used to prepare immunizations were not 
consistent across experiments. Further, some studies fed mosquitoes directly on 
immunized animals whereas others fed mosquitoes serum harvested from immunized 
animals through glass membrane feeders. 
  Cathepsin D aspartic proteases: Biochemistry and their use as immunization 
antigens against other parasites. 
 Cathepsin D aspartic proteases (CDAP) are endopeptidases whose catalytic 
activity requires two aspartic acid residues as active centers, Asp33 and Asp231 (Tang 
and Wong 1987).  The CDAPs are active in an acidic range of pH 3.0-4.5, and are 
responsible for the majority of proteolytic activity in the cellular lysosomal compartment 
(Yamamoto 1999, Minarowska et al. 2009).   A key characteristic of CDAP is that 
enzymatic catalytic activity is inhibited by pepstatin A (Barrett 1998). The role of 
aspartic proteases in the degradation of hemoglobin by blood feeding parasites is well 
documented, and in vitro and in vivo experiments targeting the CDAPs of blood feeding 
nematode parasites, immunologically and through the use of protease inhibitors, have 
shown deleterious effects on parasite physiology (Bogitsh et al. 1992, Brindley et al. 
2001, Williamson et al. 2002, Williamson et al. 2003a). 
 In nematode parasites, hemoglobin degradation occurs through a cascade of 
proteolytic cleavages, and there is overwhelming evidence that CDAP are the apical 




1992, Brown et al. 1995, Williamson et al. 2002, Williamson et al. 2003b, Williamson et 
al. 2003a).  In vitro inhibition of the CDAP of Schistosoma japonicum and Necator 
americanus through the use of pepstatin A has been shown to prevent hemoglobin 
degradation and inhibit nematode growth (Bogitsh et al. 1992, Brown et al. 1995). Also, 
RNA-interference (RNAi) mediated knockdown of CDAP transcript in Schistosoma 
mansonii has been shown to block hemoglobin digestion and inhibit parasite growth in 
vitro  (Morales et al. 2008).  Given the critical role of CDAP in hemoglobin digestion and 
survival of nematode parasites, it is not surprising that CDAP have been investigated as 
potential antigens for the development of vaccines to protect against infection with these 
parasites.  To date, two vaccines targeted against the CDAP of nematode parasites have 
been tested in vivo (Verity et al. 2001, Hotez et al. 2002). 
 In a study by Hotez et al.(2002), dogs were immunized using a recombinant 
CDAP from Ancylostoma caninum.  Dogs challenged with A. caninum L3 larvae 
exhibited an 18% reduction in worm burden in the small intestine when compared to 
control immunized dogs.  Curiously, worm burden of the colon was elevated in 
immunized dogs and the cumulative worm burden did not differ between dogs 
immunized with the recombinant CDAP and control immunized dogs.  Greater success in 
reducing adult worm burdens has been documented in a S. japonicum mouse model.  In 
this study, mice were immunized with recombinant CDAP from S. japonicum, and then 
later challenged with S. japonicum cercaria. Mean total worm burdens were reduced by 
22-40% over control immunized mice, and a reduction in the female worm burden (21-




  The mosquito lysosomal aspartic protease 
 In 1991, the Ae. aegypti lysosomal aspartic protease (AaMLAP) was isolated 
from pre-vitellogenic mosquitoes.  The enzyme was classified as a CDAP due to its 
ability to use hemoglobin as a substrate, and the fact that it was inhibited by pepstatin A 
(Cho et al. 1991).  The protein was found in the head, thorax, midgut and fat body, with 
the highest concentrations occurring in the fat body.  The complementary DNA (cDNA) 
for AaMLAP was later cloned and sequenced.  The AaMLAP mRNA and protein are 
highly upregulated following a blood meal, and reach peak levels at 24 and 42 hours, 
respectively (Cho and Raikhel 1992). 
 In mosquitoes, a multitude of proteolytic enzymes are secreted after the ingestion 
of a blood meal, with midgut trypsins being the predominant enzyme required for blood 
meal digestion (Pennington and Wells 2005).  However, there is no information on what, 
if any, role CDAP may play in blood meal digestion or hemoglobin degredation in 
mosquitoes.    Given its strong upregulation following a blood meal, AaMLAP is thought 
to play a role in the regulation of vitellogenesis (Cho and Raikhel 1992), though a precise 
mechanism is yet unknown.    
Anthelmintics and Mass Drug Administration 
  History and discovery of the avermectin and milbimycins 
 Since its discovery, ivermectin has greatly improved life for billions of people 
across the globe.  The broad-spectrum activity, safety, and relatively low cost of the drug 
have made it a potent tool in combating the devastating effects of onchocerciasis and 




 Ivermectin.  Ivermectin belongs to the class of anthelmintic drugs known as the 
avermectins.  The avermectins were discovered in 1973 through a collaborative effort 
between the pharmaceutical company Merck, Sharp and Dohme (USA) and the Kitasato 
Institute (Tokyo, Japan).  The partnership was formed to test bacterial samples for anti-
parasitic compounds, and ultimately culminated in the discovery of avermectin, which 
was extracted from the fermentation products of Streptomyces avermitilis (Burg et al. 
1979).  The ability of avermectin and milbemycin compounds to kill both endo and 
ectoparasites lead to the name ‘endectocide,’ and the word avermectin reflects the utility 
of the drug class (a- without, verm- worm, ect- ectoparasite, in- pharmaceutical product) 
(Egerton et al. 1979).  
The avermectins are 16-membered macrocyclic lactones.  Streptomyces 
avermitilis produces avermectins as a mixture of eight different components in 
fermentation, and these compounds are: A1a, A1b, A2a, A2b, B1a, B1b, B2a, and B2b (Shoop 
et al. 1995).  The most potent anthelmintic B components have a methoxy group at the 5-
position, whereas the A components have a hydroxy group (Egerton et al. 1980).  The 
major component (1) is distinguished from the (2) component by the presence of a double 
bond between the 22- and 23- carbon position.   During the fermentation process, the A-
component is produced in greater proportions than the B-component, although separation 
of the A and B components is rarely ever completed in commercial production because 
the components have nearly identical potency.  
Ivermectin (Fig 1.1) was the first commercialized drug in the avermectin drug 
class, and is synthesized by hydrogenating the cis 22,23-double bond of avermectin 




veterinary medicine in 1981, and is now routinely used in human and veterinary medicine 
as a broad-spectrum endectocide.   
Selamectin. Selamectin (Fig 1.1) is a semi-synthetic modification of doramectin, 
and belongs to the avermectin drug class.  Idiosyncratic toxicity of ivermectin in Collies 
was described shortly after the drug was marketed for use in companion animals (Paul et 
al. 1987), and selamectin was synthesized to serve as a broad-spectrum alternative.  In 
companion animals, selamectin is applied topically, and has a high efficacy against many 
endo- and ectoparasites including fleas, sarcoptic and otodectic mites, roundworms, 
hookworm and heartworm (Krautmann et al. 2000, Novotny et al. 2000).  Selamectin has 
not yet been evaluated for safety or tolerability in humans; however, the fact that it can be 
applied topically and exhibit broad-spectrum activity against a range of parasites could 
make it an attractive drug for future use in human mass drug administration (MDA) 
programs.     
Moxidectin: Moxidectin (Fig 1.1) belongs to the class of drugs known as the 
milbemycins, which are structurally very similar to the avermectins.  Milbemycins were 
discovered in 1973, and were initially used for crop protection against insects (Nakagawa 
et al. 1995) , but their utility for animal health applications has rapidly expanded.  
Naturally occurring milbemycins are fermentation products of Streptomyces 
hygroscopicus and Streptomyces cyaneogriseus (Takiguchi et al. 1980, Carter et al. 
1988).  Like the avermectins, milbemycin compounds are also subdivided into the A- and 
B-components.  Unlike the avermectins, milbimycins have a single bond between the 22- 
and 23- carbon positions, making them more structurally similar to the avermectin 2-




milbemycins have a disaccharide substituent at the 13-position of the macrolide ring (Fig 
1.1), which is lacking in the avermectins.   
  The milbimycin, moxidectin, is used in numerous veterinary applications, 
including prevention of canine heartworm, and for treatment of endo- and ectoparasites 
of livestock.  Recently, moxidectin was shown to be well-tolerated in humans (Cotreau et 
al. 2003), and is currently being evaluated for the treatment and prevention of 
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Mechanism of action and tolerability of anthelmintic drugs. 
 The avermectins and milbemycins.  Ivermectin was initially thought to exhibit 
anthelmintic activity by interfering with gamma-aminobutyric acid (GABA) chloride 
anion channels.  This early hypothesis was proposed based on the knowledge that GABA 
receptors play a critical role in nematode movement (McIntire et al. 1993).   Early 
evidence seemed to support the hypothesis in that ivermectin caused an increase in the 
chloride ion conductance of GABA channels (Kass et al. 1980, Supavilai and Karobath 
1981, Graham et al. 1982).   Further, such an effect could be inhibited through treatment 
with picrotoxin, a known GABA-gated chloride channel blocker (Olsen and Tobin 1990).  
Electrophysiology studies in nematodes, however, revealed that the concentration of 
ivermectin required to open GABA channels in nematodes, in vitro, was far beyond 
concentrations that demonstrated clear antiparasitic effects in vivo (Holden-Dye and 
Walker 1990) .  Through injecting fractionations of total mRNA prepared from 
Caenorhabditis elegans into Xenopus oocytes, two glutamate-chloride anion channel 
(GluCl) subunits were identified.  When the subunits were co-expressed, a GluCl channel 
that was sensitive to ivermectin was identified (Cully et al. 1994).   Further evidence for 
the GluCl as the target for ivermectin was provided by Dent et. al (2000), demonstrating 
that a loss of function of the avr-14, avr-15 and glc-1 genes of the GluCl channels of C. 
elegans resulted in a high level of ivermectin resistance (Cully et al. 1996b).  Ivermectin 
agonizes the GluCl channels located at the neuromuscular junctions, resulting in an influx 
of chloride ions and hyperpolarization of the nerve-cell membrane culminating in flaccid 
paralysis and death of the nematode or insect (Cully et al. 1996b, Kane et al. 2000).   
Recently, the X-ray crystal structure of ivermectin bound to the GluCl channel of C. 
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elegans was elucidated, showing that ivermectin integrates between the transmembrane 
domains of the GluCl channel subunit proteins found in the neuromuscular junctions.   
Precise mechanisms of action of the milbemycins, including moxidectin, have not yet 
been proposed; however, one study in Haemonchus contortus suggests that ivermectin 
and moxidectin bind to the same site on the H. contortus GluCl ion channel (Forrester et 
al. 2002).  
Ivermectin is well-tolerated in humans and, even at exceptionally high doses, 
serious adverse effects are rarely observed (Edwards et al. 1988).   Most adverse effects 
following treatment with ivermectin are associated with treatment in individuals with 
high microfilarial loads, and are thought to result from immunological clearing of dead 
microfilaria (Mackenzie et al. 2003).  Symptoms are generally mild and generally include 
itching, papular rashes, dermal swelling, headache, nausea and lethargy (De Sole et al. 
1989a, De Sole et al. 1989b, Pacque et al. 1989, Zea-Flores et al. 1992, Shoop et al. 1995, 
Kipp et al. 2003, Ramzy et al. 2006).   
Serious adverse effects in humans following treatment with ivermectin are rare, 
with the exception being when ivermectin is used to treat those co-infected with 
Onchocerca volvulus and Loa loa (Chippaux et al. 1996, Boussinesq et al. 1998, Kamgno 
et al. 2000).  Loa loa, commonly referred to as “eye worm” is geographically distributed 
in West and Central Africa.  Many infections are asymptomatic, and the infection is 
usually diagnosed when adult worms are detected migrating under the skin or the sclera 
of the eye (Boussinesq 2006).   Severe adverse effects observed in people that are co-
infected with O. volvulus and L. loa include confusion, lethargy, paralysis, loss of 
conscientious, and death (Gardon et al. 1997, Boussinesq et al. 1998).   
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In 2003, the tolerability of Moxidectin was assessed in healthy human volunteers.  
Moxidectin was shown to be well-tolerated with few side effects at oral doses up to 36 
mg.  Side effects were mild with no serious adverse effects observed (Cotreau et al. 
2003).  Field trials are now underway to evaluate the efficacy of moxidectin in 
onchocerciasis trials (Siva 2009). 
Currently, selamectin is only licensed for use in veterinary applications, and no 
information is available on the tolerability or safety of selamectin in humans.  
Diethylcarbamazine. Diethylcarbamazine (DEC) has been used for the control of 
lymphatic filariasis since 1948 (Gyapong et al. 2005).  Although this drug has and 
remains a mainstay in treatment of filariasis, treatment with DEC fails to clear all 
microfilaria, and has a limited effect on adult worms (Helmy et al. 2006).   Systemic 
adverse reactions to treatment, including a myriad of neurological symptoms, moderate to 
severe fever, and haematuria (blood in the urine) have been reported (Dreyer et al. 1994).  
These adverse effects have been blamed for sometimes poor patient compliance (Babu 
and Satyanarayana 2003, Babu and Kar 2004).   The precise mode of action for DEC 
remains unclear, although DEC does require host components to exhibit filaricidal 
activity.  The potential of DEC to act as an antifilarial agent was first demonstrated in a 
wood rat model (Hawking et al. 1948).   When wood rats infected with the filarial 
parasite Litomosoides carinii were given an intravenous injection of DEC, the 
microfilaria were cleared within minutes of treatment.  In vitro treatment of microfilaria 
with DEC, even at exceptionally high concentrations of 100mg/ml, failed to kill the 
microfilaria.  Although a precise mechanism of action for DEC is unknown, experiments 
with gene-knockout mice and pharmacological inhibitors indicate involvement of the 
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arachidonic acid and nitric oxide pathways in the microfilaricidal activity of DEC in vivo 
(McGarry et al. 2005).  When DEC was administered to nitric oxide knockout mice 
(iNOS-/-) which had been infected with Brugia malayi, the microfiliaria levels in the 
iNOS-/- mice were significantly greater than in the corresponding controls.  The 
involvement of the arachidonic acid pathway in the in vivo activity of DEC is supported 
by the fact that mice infected with B. malayi, and then treated with dexamethasone and 
DEC fail to significantly clear any of the microfilaria when compared to mice treated 
with only DEC (McGarry et al. 2005).   Dexamethasone exhibits anti-inflammatory 
activity by inhibiting the first stage of the arachidonic acid pathway (Yao et al. 1999).   
Albendazole. Albendazole is a broad-spectrum, orally-administered anthelmintic.  
Albendazole was first licenced for veterinary use, but was licensed for human use in 
1982.   Upon absorption, albendazole is rapidly metabolized to the active metabolite, 
albendazole-sulfoxide, which has a high systemic availablility making it a broad-
spectrum drug effective in treating difficult parasitic diseases such as echinococcosis 
(Dollery 1999).  When administered alone, and over the course of several months, 
albendazole is effective at decreasing Wuchereria bancrofti microfilaraemia (Gyapong et 
al. 2005).  When given in combination with DEC, the combination therapy is more 
effective at reducing W. bancrofti microfilaraemia than either of the drugs alone (Wamae 
et al. 2010).  Albendazole inhibits the polymerization of β-tubulin, which in turn inhibits 
the formation of microtubules, organelles required for many important cellular functions 
including the movement of chromosomes during cellular division, providing cellular 
structure, and trafficking vesicles and glucose throughout the cell (Martin 1997).    
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A number of studies have clearly demonstrated that albendazole may be a potent 
and highly efficacious drug in the treatment of bancroftian filariasis (Addiss et al. 1997, 
Dunyo et al. 2000b, a, Wamae et al. 2010), however tolerability and safety studies are 
somewhat conflicting.  While 1000 mg oral doses of albendazole were well-tolerated in 
cancer patients (Pourgholami et al. 1998), there is some evidence that a three-day course 
of albendazole could impair growth in children (Forrester et al. 1998).  Given 
albendazole’s potent and broad-spectrum activity against a number of helminth parasites, 
it is an attractive drug to consider for MDA, however given the conflicting data with 
respect to safety, further research is necessary to determine if albendazole is a drug that 
could be safely and routinely used in MDA regimens.   
Pyrantel. Pyrantel is one of four medications used for the treatment and control of 
soil-transmitted helminth infections, and is frequently administered via MDA (Hotez et 
al. 2007).  Pyrantel agonizes the synaptic nicotinic acetylcholine receptors found in 
nematode muscle cells.   Binding of pyrantel to the nicotinic acetylcholine receptor 
results in depolarization of the membrane by opening non-selective cation ion channels, 
and the influx of sodium and potassium ions results in continuous contraction of the 
muscle leading to paralysis and ultimate death of the parasite (Martin 1997).   
Reports of the tolerability and pharmacokinetics for pyrantel in humans is sparse, 
and the information that is available is conflicting.  In a study in Nigeria, nearly half of 
all patients treated with pyrantel experienced abdominal pain, nausea and dizziness (Kale 
1977), whereas another study did not report any (Sinniah et al. 1990).   
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Mass drug administration for eradication of onchocerciasis and lymphatic filariasis. 
  Onchocerciasis. 
 Onchocerciasis, also known as river blindness, is caused by infection with the 
filarial nematode, Onchocerca volvulus (Bush et al. 2001).  Onchocericasis is the second 
leading infectious cause of blindness, and occurs primarily in Africa with additional foci 
of transmission occurring in Latin America and the Middle East (Boatin and Richards 
2006).  The O. volvulus parasite is transmitted to humans through the bite of a number of 
species of black flies belonging to the genera Simulium (Robles 1917).  Larval parasites 
(microfilaria) move throughout the body, migrating to the dermal tissue and eye.   
Symptoms of onchocerciasis include severe itching, lymphadenopathy, skin atrophy, and 
depigmentation.  Interestingly, onchocerciasis symptoms are not directly caused by the 
worm, but rather by the host immune response that is mounted against a Wolbachia 
endosymbiotic bacteria that is released upon death of the microfilaria.  If microfilarial 
death occurs in the eye, the inflammatory response can result in ocular lesions and 
atrophy leading to blindness (Keiser et al. 2002).    
 Prior to the use of ivermectin, treatment of onchocerciasis was complicated for a 
number of reasons.  First, the lifespan of adult female worms can be as long as 12-15 
years.  Second, chemotherapeutic treatments are often ineffective at killing the adult 
worm (Habbema et al. 1992).   Further, the chemotherapeutic treatments with suramin or 
DEC frequently resulted in severe adverse reactions.  Suramin is a highly toxic 
compound, which is administered by the intravenous route.  Patients receiving suramin 
must be closely monitored due to the high frequency of severe adverse reactions.   
Diethylcarbamazine causes a rapid clearance of microfilaria, triggering a potent host 
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inflammatory response which frequently results in blindness (Anderson and Fuglsang 
1978).    
 Shortly after its discovery, ivermectin’s safety and efficacy in treating 
onchocerciasis was assessed in patients infected with O. volvulus (Aziz et al. 1982a, Aziz 
et al. 1982b, Coulaud et al. 1983).  Large-scale, field based trials commenced shortly 
thereafter, demonstrating that ivermectin was well tolerated in the community at large 
(Pacque et al. 1990b), as well as in patients with underlying health conditions, including 
heart arrhythmia (Dukuly et al. 1990).  Although ivermectin is not administered to 
pregnant women, inadvertent dosing of pregnant women during community-based 
treatment for onchocerciasis did not result in a significant number of birth defects in 
children born to treated mothers (Pacque et al. 1990a).     Further, community-based 
treatment was effective in suppressing the transmission of O. volvululs by Simulium spp 
(Cupp et al. 1989, Taylor et al. 1990, Trpis et al. 1990).   Ivermectin was later shown to 
have temporary embryostatic effects on adult female worms (Klager et al. 1996).  
Although the embryostatic effects are temporary, ivermectin appears to permanently 
reduce fecundity of female worms by approximately 30%  (Plaisier et al. 1995), and one 
mathematical model has predicted that if a single 150 µg/kg dose of ivermectin is given 
orally, microfilaremia could potentially be reduced by up to 98% (Basanez et al. 2008).  
A caveat to this model is that it assumes ivermectin would be ingested at a time when 
adult females are harboring few microfilaria, and it also fails to take into account 
differences in absorption and bioavailability of the drug by different patients.    
 Ivermectin was licensed under the name Mectizan for human use in 1987.  
Mectizan is generously donated by Merck, Sharpe and Dohme, Inc. for control of and 
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eradication efforts of onchocerciasis (Collins 2004).  The African Programme for 
Onchocerciasis Control (APOC) was formed in 1995 (Amazigo 2008).  The APOC was 
designed to replace the former Onchocerciasis Control Program (OCP).  The OCP relied 
nearly exclusively on aerial application of insecticides for control of black fly larvae; a 
practice, although initially effective at interrupting transmission of O. volvulus, ultimately 
proved to be prohibitively expensive and began failing due to the spread of insecticide 
resistance (Boatin 2008).  Through partnerships with the World Health Organization, 
local governments, non-governmental organizations, the private sector and the World 
Bank, the APOC is operational in delivering Mectizan to 30 African countries.     The 
Onchocerciasis Elimination Program for the Americas (OPEA) was formed in 1992.  
Prior to the start of the APOC, human onchocerciasis was reported in 13 foci located in 
six Latin American countries.   In 2008, treatment in a number of locations was stopped 
because new cases of onchocerciasis were not reported, and transmission had been halted 
in the region (Sauerbrey 2008).    Both the APOC and OPEA utilize mass drug 
administrations (MDA) of Mectizan once or twice yearly for the control of 
onchocerciasis, and use an oral dose of 150 µg/kg (Taylor and Greene 1989).   
  Lymphatic filariasis 
 Lymphatic filariasis, also known as elephantiasis, is a disease caused by infection 
with Wuchereia bancrofti, Brugia malayi or Brugia timori.   When left untreated, adult 
parasites cause blockages of the lymphatic system leading to the condition known as 
elephantiasis; an extreme swelling of the affected area.   Bancroftian filariasis, caused by 
infection with W. bancrofti, generally causes elephantiasis of the genitals.  Bancroftian 
filariasis occurs worldwide in the tropics and sub-tropics.  Brugian filariasis, caused by 
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infection with B. malayi and B. timori, occurs predominantly in Southeast Asia, and 
causes elephantiasis of the lower extremities.    All of these filariid nematodes are 
transmitted to humans as microfilaria through the bite of an infected mosquito.  Several 
genera of mosquitoes can serve as vectors for parasite transmission (Marquardt et al. 
2000). 
 In 1998, ivermectin was approved for the treatment of Lymphatic Filariasis, 
which was the same year that the Global Programme for the Elimination of Lymphatic 
Filariasis (GPELF) was formed (Hooper et al. 2009).  Traditionally, treatment of 
lymphatic filariasis relied on DEC.  However in 1997, albendazole and ivermectin were 
both shown to be effective for both treatment and control (Ottesen et al. 1997).  Shortly 
after discovering ivermectin and albendazole were also effective treatments, research 
demonstrated that two drug combinations (albendazole-DEC and albendazole-ivermectin) 
had enhanced microfilaricidal effects (Ottesen et al. 1999).  In 1998, Merck broadened 
their donation program to include donation of Mectizan for the treatment and control of 
lymphatic filariasis in areas of Africa where onchocerciasis and lymphatic filariasis both 
exist (WHO 1998a).  Also in 1998, GlaxoSmithKline pledged the donation of 
albendazole to all countries in need of the drug until eradication is complete (WHO 
1998b).  Through the use of MDA and vector control programs, the transmission of 
lymphatic filariasis has been interrupted in China and South Korea, and several other 
countries have reported considerable declines in transmission after routine MDA 
treatment of the human populations (Bockarie et al. 2009, WHO 2009).  While the goal 
for elimination of lymphatic filariasis is 2020, it is likely that eradication efforts will need 
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to extend beyond this period due to the longevity of the adult worm, and the need to 
implement vector control programs (Bockarie and Deb 2010).  
The effect of ivermectin on mosquito survival, fecundity and egg viability 
 Several reports have shown that ivermectin is effective in reducing the survival 
and fecundity of numerous vectors of human and veterinary pathogens and arthropod 
parasites.  Ivermectin has been shown to be highly toxic to the larvae of myasis-causing 
dipterans (Chamberlain 1982, Spradbery et al. 1985) and parasitic botfly larvae (Ostlind 
et al. 1979, Klei and Torbert 1980, Roncalli 1984).  In addition, ivermectin has been 
demonstrated to reduce the survival of numerous hematophagous insects including: stable 
and horn flies (Miller et al. 1986), ceratopogonids (Standfast et al. 1984), Tse-Tse flies 
(Langley and Roe 1984), sucking lice of cattle (Benz et al. 1984), and mosquitoes 
(Pampiglioni et al. 1985, Iakubovich et al. 1989b, Tesh and Guzman 1990 , Cartel et al. 
1991, Focks et al. 1991, Mahmood et al. 1991, Jones et al. 1992, Gardner et al. 1993, 
Bockarie et al. 1999, Chandre and Hougard 1999, Foley et al. 2000, Fritz et al. 2009).  In 
addition to decreasing adult insect survival, ivermectin has also been shown to decrease 
fecundity following ingestion of the drug in a bloodmeal.  This effect has been observed 
in mosquitoes (Tesh and Guzman 1990, Focks 1991, Mahmood et al. 1991, Gardner et al. 
1993) and in triatome bugs (de Azambuja et al. 1985).   
 The first report demonstrating that ivermectin could elicit a mosquitocidal 
response was conducted by Pampiglione et al. (1985).  Pampiglione and colleagues 
investigated the effect of ivermectin to induce a lethal effect in Culex quinquefasciatus, 
Aedes aegypti and Anopheles stephensi larvae and adult mosquitoes.   The effect on 
ivermectin on larvae was assessed by adding ivermectin in known concentrations to water 
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containing larvae, and then calculating the lethal concentration required to kill 50 percent 
(LC50) of the larvae.  The Cx. quinquefasciatus larvae were the most susceptible to 
ivermectin, followed by An. stephensi, and finally Ae. aegypti.  The effect of ivermectin 
on adult mosquito survival was assessed by allowing mosquitoes to feed on either cotton 
soaked with ivermectin or on mice which had been injected with an exceptionally high 
dose of ivermectin (82 mg/kg).  Survival of all mosquitoes was decreased after feeding 
on the ivermectin-soaked cotton balls and after taking a blood meal from ivermectin 
treated mice.  Curiously, despite the fact that the authors calculated the LC50 of 
ivermectin in larvae, they do not report a LC50 for either route of ingestion.  Qualitatively,  
An. stephensi was the most susceptible, followed by Ae. aegypti, and finally Cx. 
quinquefasciatus so the susceptibility of the mosquito strains to ivermectin cannot be 
directly compared.  
 In 1989, Iakubovich and colleagues allowed An. stephensi, Ae. aegypti, and 
Anopheles sacharovi to blood feed on rabbits injected with ivermectin and on blood 
containing ivermectin administered through an artificial membrane feeder.  Anopholes 
stephensi was the most susceptible, followed by Ae. aegypti, and finally An. sacharovi.  
Again, LC50 for ivermectin was not calculated. 
 The first study to empirically determine the LC50 for ivermectin imbibed through 
a blood meal in mosquitoes was completed by Tesh and Guzman (1990), who employed 
an artificial membrane feeding assay, allowing for precision in controlling the 
concentration of ivermectin fed to mosquitoes.  The LC50 values for the Ae. aegypti Rock 
strain was 126 ng/ml, the Ae. albopictus Houston strain was 208 ng/ml, and the Culex 
quinquefasciatus Gainesville strain was 698 ng/ml.  Another unique aspect of the study is 
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that it provides the first report of sub-lethal concentrations of ivermectin inducing a 
reduction in the number and viability of eggs laid by mosquitoes following a maternal 
blood meal containing a sub-lethal concentration of ivermectin.   The concentration of 
ivermectin required to prevent 50% of eggs from hatching was estimated for Ae. aegypti 
to be 3.4 ng/ml and was 4.3 ng/ml for Ae. albopictus.  While the effects of ivermectin on 
larvae had previously been reported (Ali and Nayar 1985, Pampiglioni et al. 1985), the 
report by Tesh and Guzman was the first to report that when ingested in a blood meal, 
ivermectin could significantly decrease the fecundity and egg viabilitiy in mosquitoes.  
Unlike in the triatome Rhodnius prolixus (de Azambuja et al. 1985), the infertility 
observed in Ae. aegypti was temporary, and diminished after feeding on a second blood 
meal that did not contain ivermectin.   
The effects of ivermectin on the ovarian development and egg viability were 
further investigated by Focks et al. (1991) and Mahmood et al. (1991).  Focks and 
colleagues injected rabbits with ivermectin at a concentration of ivermectin 10 and 50 
times greater than the labeled dose recommended in cattle.   Mosquitoes who fed on the 
rabbits injected with the high dose exhibited reduced survival.  Mosquitoes that survived 
oviposited significantly fewer eggs than control-fed mosquitoes, and eggs were less likely 
to hatch, and survival of larvae was lower than observed in controls.    Mosquitoes that 
had fed on rabbits injected with the lower dose of ivermectin did not experience a 
reduction in survival, and no significant effects on fecundity or hatch rate were observed 
relative to control fed mosquitoes.  A drawback to the study design used by Focks et al. 
(1991) is that the concentration of ivermectin imbibed by blood feeding mosquitoes was 
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not quantified, making it difficult to relate the results from the study to relate the findings 
of the study to potential impact of ivermectin on field populations of mosquitoes.   
The effect of ivermectin on the ovarian development of Ae. aegypti was 
investigated by Focks et al. (1991).  Utilizing the artificial membrane feeding assay 
described by Tesh and Guzman (1991),  Ae. aegypti (Rock strain) mosquitoes were fed 
on blood containing ivermectin at a concentration of 100 ng/ml.  Mosquitoes which had 
ingested blood containing the ivermectin experienced a 23.5% decrease in survival over 
controls.  Mosquitoes which had ingested blood containing ivermectin exhibited a 
significant reduction in follicle and yolk length when compared to controls.  A significant 
reduction in egg production was also observed by females which had ingested ivermectin.  
Eggs that were laid were abnormal in size, and exhibited reduced hatching.  Interestingly, 
many of the eggs which failed to hatch contained viable larvae.  Based on the lipophilic 
nature of ivermectin, the authors hypothesize that ivermectin may be incorporated into 
the egg and prevent hatching.  This hypothesis remains untested, and the precise 
mechanism through which ivermectin induces infertility and prevents egg hatching has 
not yet been elucidated.    
 The first study to report a reduction in mosquito survival after feeding on humans 
that had been treated with an MDA drug was conducted by Cartel et al. (1991).  The 
study was designed to evaluate the safety and efficacy of a single dose of ivermectin for 
the treatment of bancroftian filariasis, and to evaluate the efficacy of three treatment 
regimens for their effect on transmission by laboratory raised Aedes polynesiensis 
mosquitoes.  Surprisingly, Ae. polynesiensis which had fed on ivermectin and DEC 
treated patients at one, three and six months post-treatment experienced significantly 
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higher mortality when compared to mosquitoes fed on placebo-treated patients.  Mortality 
was significantly greater in mosquitoes fed on carriers treated with ivermectin than those 
treated with DEC.  The six-month longevity of the mosquitocidal response following 
treatment with ivermectin has not been replicated in human studies or any other animal 
system, and the results remain rather perplexing.  The authors speculate that the longevity 
of the mosquitocidal response may have been due to deposition and persistence of 
ivermectin in human tissues.  Since the report by Cartel et al. (1991), a handful of studies 
have investigated mosquito survival following MDA treatment of human populations 
(discussed below), and none have seen such a long-lived mosquitocidal effect, suggesting 
that deposition of ivermectin in tissues is not a likely cause for the results reported. 
 The first study to quantify circulating concentrations of ivermectin at the time of a 
mosquito blood feed was conducted by Jones et al. (1992).  Dogs were injected with 
varying concentrations of ivermectin. Twenty-four hours after ivermectin administration, 
blood from the dogs was collected and offered to Anopheles quadrimaculatus mosquitoes 
through a membrane feeder.  A portion of the blood was reserved for quantification of 
ivermectin in the blood.   Mosquitoes which had imbibed blood from dogs containing 
ivermectin at a concentration of 33-37 ng/ml experienced 65% mortality.   The mean 
maximal concentration of ivermectin in human blood following a standard MDA dose of 
ivermectin is 46 ng/ml (Elkassaby 1991).  The findings of Jones et al. (1992) are 
significant in that they were the first to demonstrate that a mosquito was susceptible to a 
concentration of ivermectin which could be expected in vertebrate blood following a 
treatment with ivermectin.  Gardner et al (1993) conducted a similar study in which dogs 
were given oral doses of ivermectin.  Laboratory raised Ae. albopictus, and field caught 
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An. quadrimaculatus and Culex salinarius were allowed to blood feed directly on the 
dogs.  After the blood feed, dogs were bled and the concentration of ivermectin 
circulating at the time of blood feed was quantified.  Depending on the oral dose of 
ivermectin administered to the dog, the concentrations of ivermectin circulating in the 
blood ranged from 0 ng/ml (controls) to 16 ng/ml (dogs given a 24 µg/kg dose of 
ivermectin).  After feeding on ivermectin-treated dogs, increased mortality was observed 
in An. quadrimaculatus which had fed on dogs that had received either a 12 or 24 µg/kg 
dose of ivermectin.  No reduction in survival was observed in Ae. albopictus or in Cx. 
salinarius after feeding on treated dogs, even at an oral dose of 120 µg/kg.  The fecundity 
and hatch rates of An. quadrimaculatus were significantly decreased after feeding on 
dogs treated with increasing concentrations of ivermectin, and egg hatching was 
completely  inhibited from blood meals taken from dogs treated with a 24 µg/kg dose of 
ivermectin.  A reduction in hatch rate, but not overall fecundity, was observed in Ae. 
albopictus after a maternal blood meal from dogs treated with 15, 30, 60, and 120 µg/kg 
of ivermectin.  Fecundity and hatch rate of Cx. salinarius was not affected.   
  Chandre and Hougard (1999) observed a 25% reduction in the survival of Cx. 
quinquefasciatus after feeding on chickens injected with a 2,000 µg/kg dose of 
ivermectin, and did not see any death in mosquitoes fed on humans treated with a 
therapeutic dose of 170 µg/kg. Since the report by Chander and Hougard (1999), focus 
has shifted towards investigating the effects of ivermectin on Anopheles spp. mosquitoes. 
 The first field study to investigate the effects of MDA treatment with anthelmintic 
drugs on the survival of endemic populations of mosquitoes was conducted shortly after 
the formation of the GPELF, and investigated the effects of experimental MDA doses 
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(given to evaluate their efficacy to interrupt transmission of W. bancrofti) on the survival 
of Anopheles punctulatus mosquitoes.  The two MDA regimens included: mass treatment 
of a village with a single dose of 400 µg/kg ivermectin + 6 mg/kg DEC, and 400 µg/kg of 
ivermectin only.  For the 400 µg/kg ivermectin + 6 mg/kg DEC MDA treatment, blood 
fed mosquitoes were collected from homes for three consecutive days immediately prior 
to and after the MDA.  At 28 days post-MDA, blood fed mosquitoes were again 
collected.  Survival of collected mosquitoes was monitored for nine days.  The survival of 
mosquitoes after MDA treatment was significantly reduced (n=36), with 100% mortality 
reported within nine days.  Survival of mosquitoes caught post-treatment over the course 
of nine days was significantly lower survival of mosquitoes captured pre-treatment or 28 
days post-treatment.   
To evaluate the effect of a single 400 µg/kg ivermectin dose of ivermectin on 
mosquito survival, the authors compared the survival of mosquitoes caught in the MDA 
treated village to survival of mosquitoes caught in a control village. The control village 
had, however, been treated with DEC two months prior to the experiment, but did not 
receive ivermectin.  Mosquito survival was monitored for 48 hours, and was significantly 
lower (94%) in the ivermectin treated village when compared to the control village.  At 
38 days post-treatment, mosquito survival was similar between villages.   The study by 
Bockarie et al. (1999) suffers from some experimental design flaws.  The sample sizes of 
mosquitoes for the 400 µg/kg ivermectin + 6 mg/kg DEC study group were relatively 
small, and were only collected from nine homes.  Secondly, the control village used for 
the 400 µg/kg ivermectin MDA treatment was not an optimal control.  The control village 
had been treated two months prior with DEC whereas the village treated with ivermectin 
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only had not.  However, it does not appear from the results that DEC had any effect on 
the survival of mosquitoes in the control village.  Despite some experimental design 
flaws, the findings from this report are significant in that they are the first to show that a 
MDA dose of ivermectin, albeit higher than the 150 µg/kg dose now used, can be 
effective in reducing the daily survival of field caught mosquitoes.   
The effect of ivermectin on the survival of other Anopheles species has also been 
investigated.  Foley et al. (2000) found that survival of a laboratory strain of  Anopheles 
farauti was decreased after feeding on a human volunteer for close to a week following 
ingestion of a single 250 µg/kg dose of ivermectin.  An important downfall of the study 
design is that an untreated volunteer was not included as a control.  Mortality data 
collected at the various time points post-feeding was compared to survival of mosquitoes 
that fed on the human volunteer prior to administration of the ivermectin.  Presumably, 
each blood feed used a different cohort of mosquitoes.  Given that survival of mosquitoes 
was assessed at different times, one cannot rule out environmental factors that may have 
contributed to the survivorship of mosquitoes.   Regardless, this study appears to provide 
some evidence that An. farauti is susceptible to ivermectin in human blood following oral 
ingestion, although the 250 µg/kg dose ingested by the human volunteer is 100 µg greater 
than the dose frequently used in human MDA campaigns.   
Anopheles gambiae s.s. and Anopheles arabiensis are two of the most important 
vectors of human Plasmodium in Africa, and both were demonstrated to be susceptible to 
ivermectin at concentrations which could be expected to be found circulating in human 
blood(Fritz et al. 2009).  Using an in vitro feeding assay, Fritz and colleagues determined 
the LC50 of An. gambiae s.s. (Kisumu strain) and An. arabiensis (Dongola strain) to be 
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19.8 parts per billion (19.8 ng/ml).  The authors also observed a significant reduction in 
survivorship of An. gambiae s.s. after feeding on ivermectin treated bulls, relative to An. 
gambiae that had fed on saline injected cattle.  From their findings, they conclude that 
treatment of cattle with ivermectin could be used to reduce zoophilic vector populations 
that are responsible for some transmission of human malaria.  These conclusions may be 
premature, as the cattle were injected with a 600 µg/kg dose of ivermectin; a dose three 
times greater than the recommended dose in cattle.  Further, their experimental design 
utilized An. gambiae s.s., which is known to be a highly anthropophillic, not a zoophilic 
vector (Besansky et al. 2004). 
Fritz et al (2009) also observed that ingestion of ivermectin at a concentration of 
greater than 10 ng/ml was associated with complete infertility in both An. gambiae and 
An. arabiensis.  Egg production in An. gambiae mosquitoes which had fed on ivermectin 
treated bulls appeared to be inhibited if they had fed within 10 days of the treatment, and 
oviposition by mosquitoes that had taken blood meals at 13 and 17 days post treatment 
exhibited a significant reduction in overall fecundity when compared to control fed 
mosquitoes.  Mosquitoes which had fed at 20 and 23 days post treatment did not exhibit 
reduced fecundity.  Neither An. gambiae or An. arabiensis produced eggs after feeding on 
ivermectin at concentrations of 10, 100 and 1,000 ng/ml.  Neither egg production nor 
hatch rate was affected at concentrations of 0.01, 0.1 or 1.0 ng/ml.   
An. gambiae was later demonstrated to be susceptible to ivermectin circulating in 
the blood of humans following ingestion of a 200 µg/kg dose (Chaccour et al. 2010).  
Twenty-four hours after treatment, the mean survival of mosquitoes fed on ivermectin-
treated humans was 2.3 days, whereas mean survival in the control-fed mosquitoes was 
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5.5 days.   Mosquito survival was not affected after feeding on ivermectin treated 
individuals 14 days after treatment.   
Recently, MDA of ivermectin was shown to significantly reduce the survival of 
field caught An. gambiae s.l. and An. arabiensis (Sylla et al. 2010).  Significant 
reductions in An. gambiae s.l. survival were observed for up to six days following a 
single MDA treatment of ivermectin (150 µg/kg), which covered approximately 80% of 
the villagers in the study sites.  From the experimental data, it was estimated that the 
daily probability of mosquito survival was decreased by at least 10% during the six days 
after MDA of ivermectin.  Given the estimated reduction of daily probability of mosquito 
survival and an age-structure model for malaria transmission, it was estimated that a 
single MDA dose of ivermectin could reduce the reproductive rate of malaria, suggesting 
that repeated MDAs of ivermectin could have a considerable impact on the transmission 
of malaria.   The model proposed by Sylla et al. (2010) was supported by field data in 
2011 (Kobylinski et al. 2011).  Kobylinski et al. (2011) observed that the sporozoite rate 
of An. gambiae mosquitoes captured in MDA treated villages decreased by nearly 80%, 
whereas sporozoite rates in a nearby, untreated control village did not.   
Ivermectin resistance and cross-resistance. 
 Ivermectin was licensed for veterinary use in 1981, and shortly thereafter was 
approved for use in humans.  Ivermectin and closely related compounds are widely used 
in agriculture, veterinary and human medicine.  Resistance in nematode parasites and 
insects has been documented, and is reviewed below.  
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  Ivermectin resistance in nematodes. 
 Reports of suboptimal treatment responses of O. volvulus microfilaria with 
ivermectin have been reported (Addiss et al. 1991, Awadzi et al. 2004b, Awadzi et al. 
2004c, Awadzi et al. 2004a, Osei-Atweneboana et al. 2007, Osei-Atweneboana et al. 
2011).  In all of these reports, treatment with ivermectin resulted in an immediate 
reduction of microfilaria observed in skin snips.  However, despite multiple treatments 
with ivermectin, microfilaria counts at later time points were elevated.  The initial dose of 
ivermectin is not effective at killing adult worms and has no effect on their reproduction, 
and subsequent and repeated treatments with ivermectin are required, and are generally 
successful, in impairing the ability of adult female worms to produce microfilaria 
(Chavasse et al. 1992).  Thus, the higher than expected microfilaria counts suggest that 
multiple treatments with ivermectin failed to decrease microfilaria production by adult 
female worms.  In a recent study by Osei-Atweneboana et al. (2011), nodules containing 
adult O. volvulus were surgically removed from patients that had failed to respond to 
repeated treatments with ivermectin.  Adult worms from the nodules were observed, and 
morphological examination revealed that nearly 90% of the worms were older worms, 
providing phenotypic evidence that resistance to ivermectin could be developing in O. 
volvulus.   
 Ivermectin resistance has been documented in numerous other nematode 
parasites, some of which include: Haemonchus contortus (Paiement et al. 1999), 
Trichostrongylus (Traversa et al. 2007), and Cooperia oncophora (Njue et al. 2004).  
Precise mechanisms of resistance to ivermectin have not been elucidated, and may vary 
between parasites.  In C. elegans, high-level resistance to ivermectin appears to be 
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polygenic, requiring the simultaneous mutation of three GluCl α-type subunits (Dent et 
al. 2000).  In H. contortus, radio-labeled ivermectin did not differ in its ability to bind to 
membranes of the worm, suggesting that target site-mutations are not responsible for 
ivermectin resistance observed in a laboratory-selected strain (Paiement et al. 1999).   Yet 
another potential mechanism for ivermectin resistance is P-glycoprotein mediated drug 
efflux.  P-glycoproteins are known to pump drugs across membranes thereby preventing 
them from reaching their target sites (Kerboeuf et al. 2003b), which has been associated 
with macrocyclic lactone resistance in several nematode parasites (Blackhall et al. 1998, 
Xu et al. 1998, Le Jambre et al. 2000, Kerboeuf et al. 2003a, James and Davey 2009). 
  Ivermectin resistance in insects and other arthropods. 
 The most comprehensive selection studies with any avermectin in an insect have 
been conducted in the Colorado potato beetle (Argentine and Clark 1990).  Argentine and 
colleagues generated, by different procedures, two different abamectin resistant strains.  
One of the strains was generated by placing a field strain through intensive laboratory 
selection, and the other was produced by treating a susceptible laboratory strain with a 
chemical mutagen in conjunction with discriminatory dose selection with abamectin.  
Crosses of the resistant lines with the susceptible laboratory strain indicated that 
resistance in both strains was incompletely recessive, based on the finding that the F1 
offspring resulting from a mating between the susceptible and resistant strains was less 
resistant to abamectin than what would be expected in an intermediate phenotype 
(Argentine et al. 1992).  Log dose versus logit mortality regression lines were calculated 
for the susceptible laboratory strain, the abamectin-resistant strains, and their F1 
offspring.   Overlap of the regression lines indicated that inheritance of abamectin 
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resistance in both selected strains was polygenic (Georghiou 1969).   Although a specific 
mechanism for abamectin-resistance was never identified in the resistant lines, 
experiments utilizing metabolic synergists are indicative of metabolic resistance 
(Argentine et al. 1992).  Treatment of the resistant lines with piperonyl butoxide (a mixed 
function oxidase inhibitor) resulted in increased toxicity of abamectin to both lines, and 
treatment with S,S,S-tributyl phosphorotrithioate (an esterase inhibitor) resulted in 
moderate levels of increased toxicity in the abamectin-resistant strains.  Treatment of the 
strains with glutathione-S-transferase inhibitors did not elicit an increased toxicity effect 
of abamectin.  Collectively, the results are suggestive of a metabolic resistance 
mechanism involving mixed function oxidases, and perhaps to a lesser degree, esterases.  
Studies with radiolabeled avermectin were not suggestive of a decreased cuticular 
penetration mechanism of resistance.  
 Low-level ivermectin resistance was achieved in sheep blow fly larvae after 60 
successive rounds of selection, achieving an eight-fold increase in tolerance to ivermectin 
when relative to the parental strain (Rugg et al. 1998).  Increased monooxygenase 
activity, measured through a microsomal bioassay, were slightly elevated in the resistant 
strain, but were not significantly greater than observed in the parental line.   
 Ivermectin has been used successfully for the treatment of crusted scabies, a skin 
condition caused by infestation with the mite, Sarcoptes scabiei (Lawrence et al. 2005), 
and has been used successfully for treatment of severe infestations.  Recently, however, 
recrudescent infestations after treatment with ivermectin have been reported, requiring 
multiple doses of ivermectin or high concentrations of topical permethrin to cure patients 
of the infestation (Huffam and Currie 1998, Walton et al. 1999, van den Hoek et al. 
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2008).  The precise cause for the recrudescent infestations has not been determined, and 
the failure of ivermectin to cure the infestations is not enough to conclusively state 
whether or not resistance is developing in S. scabiei.  Other factors such as patient 
compliance and living conditions may play a role in the cure rate.  In one report, Currie 
and colleagues (2004) claim the first documentation of in vivo and in vitro ivermectin 
resistance in S. scabiei mites that were obtained from two patients, both of whom failed 
to respond to over 30 oral doses of ivermectin.  Mites were collected from patients at 
various points over the course of five years.  At each collection, mites were immediately 
subjected to an in vitro assay where their time to death was measured after exposure to a 
predetermined concentration of ivermectin.   In one of the patients, the time to death for 
mites collected in the year 2000 was significantly greater than the time to death for mites 
collected in 1999 or 2001.  The patient is reported to have received 30 doses of 
ivermectin between 1995 and 2000, but no discussion is provided as to how patient 
compliance with the regimen was assessed.  Further, the in vitro assays on mites collected 
at different times were not conducted concurrently, rather they were separated by years.  
For a number of reasons, it is questionable as to whether the data from the two 
experiments should be directly compared.  Nonetheless, the occurrence of ivermectin 
failure in the treatment of scabies is of notable concern and should continue to be 
monitored.  
Cross-resistance between avermectins and other insecticides.   
Cross-resistance between the avermectins and other classes of insecticides is 
poorly understood, and reports of its occurrence and lack thereof are conflicting.  The 
most recent report of cross-resistance to ivermectin demonstrated that Drosophila 
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melanogaster which had been laboratory selected for resistance to nodulisporic acid were 
3-fold cross-resistant to ivermectin.  Both nodulisporic acid and ivermectin target the 
GluCl channel.  Sequencing of the GluCl alpha subunit revealed a proline to serine 
mutation.  Recombinant mutant GluCl channels expressed in Xenopus oocytes were 
highly insensitive to activation by nodulisporic acid and ivermectin, indicating that a 
target site mutation was responsible for both resistance to nodulisporic acid as well as 
nodulisporic acid-induced cross-resistance to ivermectin (Kane et al. 2000).    
Other than the study by Kane et al. (2000), most cross-resistance studies have 
used abamectin (avermectin B1a).  The first report of cross-resistance between abamectin 
and permethrin was observed in a laboratory-selected permethrin resistant strain and a 
field-collected strain of Musca domestica (Scott 1989).  The laboratory-selected 
permethrin resistant strain and field collected strain had a 25-fold and 5.9-fold cross-
resistance (relative to a laboratory susceptible strain) to abamectin.  A topical bioassay 
was used to determine cross-resistance ratios.   The field strain used in the study was 
collected from a dairy reporting failure of permethrin insecticides, and was shown to have 
a high level of permethrin resistance relative to the standard susceptible strain.  To 
determine whether the increased tolerance to abamectin in the laboratory-selected 
permethrin resistant strain was truly due to a cross-resistance mechanism rather than a 
difference in tolerance between strains, the researchers employed an F1 backcross where 
susceptible females with known genetic markers were crossed with F1 males.  Offspring 
from the mating were treated with a diagnostic dose of abamectin, and the effect of each 
chromosome was estimated using an arcsine of the percentage of survival, allowing for 
statistical analysis of a specific gene’s contribution to resistance.   From the genetic 
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analysis, three possible mechanisms for the observed resistance were identified: increased 
metabolism via mixed-function oxidase (MFO), knock-down resistance (kdr) 
insensitivity, and decreased cuticular penetration.  Treatment of flies with piperonyl 
butoxide (an inhibitor of MFO) suppressed resistance to abamectin in the permethrin-
resistant line and increased the toxicity of the drug in the susceptible strain.  Given that 
permethrin and abamectin have different molecular targets, the researchers concluded 
that the cross-resistance was likely due to increased metabolic resistance and decreased 
cuticular penetration.    
While cross-resistance between other insecticides and abamectin have been 
reported in other insects, including the German cockroach (Scott 1991) , the diamond 
back moth (Abro et al. 1988) , and the sheep blow fly larvae (Hughes and Levot 1990) , 
the studies by Kane et al. (2000) and Scott (1989) are the only ones to propose possible 
mechanisms for cross-resistance to avermectin compounds.   Abro et al. (1988) used a 
topical bioassay to examine the level of cross-resistance to abamectin in a “field strain [of 
the diamond-back moth, Plutella xylostella] showing multiple resistance to insecticides.”  
The authors propose that a “low-level of cross-resistance to avermectin could be present 
in the field strain,” however they also point out that the field strain was equally 
susceptible to abamectin as a baseline colony, making it difficult to interpret whether or 
not a cross-resistance mechanism was really observed.  Scott (1991) observed  
significantly higher LD95 values for abamectin in two multiresistant German cockroach 
lines, relative to a laboratory susceptible strain.   The resistance to other insecticides in 
the cockroach lines was poorly defined, and it was impossible to determine which 
insecticide or insecticides were associated with observed cross-resistance to abamectin.   
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Low level cross-resistance to ivermectin and abamectin was observed in an 
organophosphate and carbamate laboratory selected line of the sheep blowfly (Hughes 
and Levot 1990);  however, after selecting the same strain for pyrethroid and carbamate 
resistance, the strain was later shown to be susceptible to ivermectin (Rugg et al. 1995).   
 While there is a handful of reports that suggest cross-resistance between 
avermectins and other insecticides may occur, there is an equal number of reports that 
have found no evidence of this phenomenon; further, reports are conflicting.  One study 
found no evidence of cross-resistance to avermectins in house flies known to be resistant 
to diazinon, dieldren, DDT and permethrin (Roush and Wright 1986a).  The literature is 
also conflicting in the case of the German cockroaches.  While Scott (1991) observed a 
possible cross-resistance phenomenon, another study in the German cockroach found that 
field-selected pyrethroid-resistant cockroaches were fully susceptible to abamectin 
(Cochran 1990).  Pyrethroid-induced cross-resistance was not observed in a strain of 
tobacco budworm which displayed both metabolic and target site resistance to 
pyrethroids (Campanhola and Plapp 1989).  Similarly, cross-resistance studies in a 
multiple insecticide resistant strain of Colorado potato beetle showed no evidence of 
cross-resistance to abamectin (Argentine and Clark 1990).   To date, the only studies of 
cross-resistance to ivermectin in hematophagous insects have been in head lice, and to 
date studies indicate that permethrin-resistant headlice are susceptible to ivermectin both 
in vitro (Strycharz et al. 2008), and in vivo(Chosidow et al. 2010).  Ultimately, the 
occurrence of cross-resistance between the avermectins and other insecticide classes in 
insects is both poorly understood and ill-defined. With the exception of head lice, most 
research has focused on domestic and agricultural insect pests.   Further, all studies 
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except for those in the German cockroach and head louse have employed topical 
bioassays to evaluate the occurrence of cross-resistance.   
The effect of oral ingestion of an avermectin compound in hematophagous insects 
is largely unexplored.  The uses of ivermectin are rapidly expanding beyond endo and 
ectoparasite control.  Some have pointed out that ivermectin could someday be used to 
control mosquito-borne diseases such as malaria (Foy et al. 2011).  Given the wide-
spread reports of ivermectin resistance in many organisms, and in light of some evidence 
of cross-resistance (coupled with the fact that insecticide resistance is wide-spread and 
expanding), investigating the likelihood for the development of ivermectin-resistance or 
cross-resistance in hematophagous vector species, such as the mosquito is warranted.   
Summary  
 Arboviral pathogens transmitted by Ae. aegypti impart a tremendous global 
burden of disease.  Traditional control methods for many of these pathogens are failing 
due to the rapid spread of insecticide resistance.   Global travel and shipping routes 
present a constant risk of introducing both Ae. aegypti and pathogens transmitted by the 
vector into new geographic locations.  Novel methods for interrupting transmission of 
mosquito-borne pathogens are needed, and it has been suggested that mosquitocidal 
vaccines and MDA of anthelmintic drugs could be effective tools (Billingsley et al. 2008, 
Foy et al. 2011).  The work presented here was designed to evaluate antigens of Ae. 
aegypti for their potential for inducing mosquitocidal activity (Chapter 2), to evaluate the 
effect of anthelmintic drugs on Ae. aegypti (Chapter 3), and to evaluate differences in 
susceptibility of different strains of Ae. aegypti to ivermectin and to investigate whether 
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Research Objective and Hypotheses. 
 The objective of the research outlined in this chapter was to evaluate the Aedes 
aegypti mosquito lysosomal aspartic protease (AaMLAP) and glutamate gated chloride 
anion channel (GluCl) as antigens for inducing mosquitocidal immunity in mice.  The 
hypotheses for this chapter are the following: 
1. If the AaMLAP is a mosquitocidal antigen, then mosquitoes that imbibe blood 
meals from mice immunized against AaMLAP will experience reduced 
survival because immune components ingested in the blood meal will attack 
the native AaMLAP protein in the mosquito. 
2. If the glutamate gated chloride anion channel is a mosquitocidal antigen, then 
mosquitoes that imbibe GluCl antiserum will experience reduced survival 
because binding of the antibody to the GluCl channel will disrupt channel 
function.   
Introduction. 
Ae. aegypti is one of the most important mosquito vectors of human arboviruses.  
To date, the most successful attempts at controlling transmission of arboviruses vectored 
by Ae. aegypti in human populations have involved the use of insecticides (World Health 
Organization 2006), but their utility is rapidly diminishing due to the rapid emergence 
and spread of insecticide resistance (Castle et al. 1999, Jirakanjanakit et al. 2007b, 
Jirakanjanakit et al. 2007a, Pethuan et al. 2007).  Consequently, novel methods to control 
the mosquito vector are urgently needed, and some have argued that the use of 
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mosquitocidal vaccines could be a novel method to help contol the transmission of 
mosquito-vectored pathogens (Foy et al. 2002, Billingsley et al. 2008).   
Hematophagous insects, such as Ae. aegypti, imbibe blood for nutrition and egg 
production and maturation.  When a mosquito feeds on a host, it ingests immune 
components circulating in the host’s bloodstream.   A mosquitocidal vaccine (reviewed in 
Chapter 1) would immunize a host against antigens from the mosquito tissue.   If immune 
components mounted against mosquito antigen were imbibed by a blood feeding 
mosquito, then they could bind the antigen within the mosquito, ultimately leading to 
mosquito death (Foy et al. 2002).    
Anti-vector immunity was first demonstrated in 1939, when William Trager 
immunized guinea pigs and rabbits with crude tick extracts from the tick Dermacentor 
variabilis.  Ticks which had fed on immunized animals experienced significant mortality, 
or failed to engorge  (Trager 1939b, a).  Nearly sixty years after Trager’s discovery, two 
recombinant protein anti-tick vaccines, were developed and licensed for use in cattle for 
protection against Boophilus microplus, and both vaccines incorporate the recombinant 
protein, Bm86 (Willadsen et al. 1995b, de la Fuente et al. 1999).   These vaccines have 
been shown to only reduce tick-burden on treated animals (Rodriguez et al. 1995a, 
Rodriguez et al. 1995b, Canales et al. 1997), and may also reduce the transmission of 
tick-borne pathogens (Pipano et al. 2003, Labuda et al. 2006).   
Progress in identifying mosquitocidal antigens has been slow.  Historically, 
mosquitocidal immunity has been demonstrated through immunizing animals against 
crude mosquito homogenates (Alger and Cabrera 1972, Hatfield 1988, Almeida and 
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Billingsley 1998, 1999, Lal et al. 2001, Almeida and Billingsley 2002).  To date, only 
two mosquitocidal antigens have been described; the Anopheles gambiae Mucin-
1(AgMucI) protein (Foy et al. 2003) and the Aedes albopictus subolesin protein (Canales 
et al. 2009).  No reports of specific mosquitocidal antigens for Ae. aegypti have been 
published.  In this report, we evaluated the Ae. aegypti mosquito lysosomal aspartic 
protease (AaMLAP) and the glutamate-gated chloride anion channel (GluCl) as potential 
mosquitocidal antigens.   
In 1991, the AaMLAP was isolated from previtellogenic mosquitoes.  Due to its 
ability to use hemoglobin as a substrate and inhibition of activity by pepstain A, the 
AaMLAP was identified as belonging to the cathepsin D family of proteases (Cho et al. 
1991).  The protein was found in the head, thorax, mid-gut, and fat body, with the highest 
concentrations occurring in the fat body, and a putative secretion signal sequence was 
identified.  The cDNA coding for AaMLAP was later cloned and sequenced, and 
AaMLAP mRNA and protein were shown to be highly upregulated after blood feeding. 
The AaMLAP mRNA abundance increased between six and twelve hours following a 
bloodfeed and reached peak levels at 24 hours post bloodmeal.  AaMLAP protein levels 
reached peak concentrations between 36 and 42 hours following a bloodmeal (Cho and 
Raikhel 1992). 
 Orthologs of the AaMLAP protein have been described in several blood feeding 
nematodes, including in Schistosoma japonicum, Schistosoma mansonii, and 
Ancylostoma caninum. In vitro and in vivo immunologic targeting of these parasites has 
been shown to induce pathology in the parasite and decrease survival.  In vitro incubation 
of S. japonicum with bovine antiserum against S. japonicum cathepsin-D, resulted in 
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decreased hemoglobin degradation and disruption of the tegument and gastrodermus of 
the worm (Bogitsh et al. 1992).  Dogs immunized with a recombinant A. caninum 
cathepsin-D aspartic protease protein exhibited an 18% reduction of worm burden of the 
small intestine (Hotez et al. 2002), and mice immunized with a recombinant S. japonicum 
cathepsin-D aspartic protease protein exhibited 22-40% reductions in overall worm 
burden (Verity et al. 2001).      
   In mosquitoes, a multitude of proteolytic enzymes are secreted after the 
ingestion of a bloodmeal with midgut trypsins being the predominant enzyme required 
for bloodmeal digestion (Pennington and Wells 2005).  While it has been proposed that 
AaMLAP is important in the regulation of vitellogenesis (Cho and Raikhel 1992), 
whether or not the enzyme plays a role in mosquito blood meal digestion is unknown   A 
sequence alignment revealed an amino acid sequence identity of 57.3% between 
AaMLAP and S. japonicum CDAP.  When conserved replacements are considered, the 
similaratiy is 85%.   Given that AaMLAP mRNA and protein are upregulated following a 
blood meal, and immunizations against orthologous cathepsin-D aspartic proteases are 
effective in decreasing worm burdens in vivo, we hypothesized AaMLAP could be used 
as an antigen to elicit mosquitocidal immunity in Balb/c mice.  To test this hypothesis, 
we generated four different immunization constructs, and tested them for their ability to 
induce mosquitocidal immunity in mice by using different immunization regimens. The 
immunization constructs included: two DNA immunization plasmids, a recombinant 
Sindbis virus vector containing the AaMLAP gene, and a recombinant AaMLAP protein 
produced in Escherichia coli cells.  The four different immunization regimens included: 
immunization with the DNA immunization plasmids co-administered with mouse IL-12 
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(mIL-12) adjuvant plasmid  (administered either by intramuscular (i.m.) injection or 
delivered intradermally (i.d.) using a gene gun), i.m. DNA immunization followed by a 
boost with the live AaMLAP-Sindbis virus expression vector, and finally subcutaneous 
(s.c.) immunization with a polyacrylamide gel slurry containing the recombinant protein 
expressed from E. coli cells.   
 In this chapter, we also investigated the Ae. aegypti GluCl anion channel as a 
potential mosquitocidal target.  GluCl  ion channels belong to the cys-loop superfamily of 
neurotransmitters, and are responsible for modulating synaptic inhibition in neurons and 
muscle fibers of many invertebrate animals, including insects (Cleland 1996).  
Avermectins, such as ivermectin, are GluCl receptor agonists which bind selectively to 
GluCl receptors in the nerve and muscle cells of invertebrates (Arena et al. 1992, Cully et 
al. 1996a, Cully et al. 1996b).  Ivermectin has been shown to be highly effective in killing 
mosquitoes when it is imbibed with a bloodmeal (Pampiglioni et al. 1985, Tesh and 
Guzman 1990, Cartel et al. 1991, Jones et al. 1992, White 1997, Foley et al. 2000, Fritz et 
al. 2009, Kobylinski et al. 2010, Sylla et al. 2010).   Given the success of ivermectin in 
inducing mosquitocidal activity when ingested with a bloodmeal, we hypothesized that 
Ae. aegypti fed on heterologous GluCl antisera would exhibit reduced survival when 
compared to mosquitoes fed on control serum.  We tested this hypothesis by feeding Ae. 
aegypti on rabbit polyclonal antisera which had been raised against the extracellular 
domain of recombinant An. gambiae GluCl protein using an in vitro feeding system.  The 
amino acid sequence identity between the extracellular domains of the GluCl anion 
channel of Ae. aegypti and An. gambiae is 75%.  When conserved amino acid 
replacements are considered, the sequence similarity is 90%.    
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Materials and Methods. 
Mosquitoes.  
The Ae. aegypti Rexville D- Higgs White Eye (HWE) strain was used for all of 
the experiments in this chapter.  Mosquitoes were reared at 28°C ± 2°C, 80% relative 
humidity, under a photoperiod of 14:10 (L:D).  Larvae were reared in 28 liter (L) 
containers filled with approximately 15 L of tap water.  Mosquito larvae were fed a diet 
of ground Tetramin® fish food mixed with ground mouse food.  Adult mosquitoes were 
offered water and raisins as a sugar source ad libitum. 
Production and administration of AaMLAP-DNA immunization construct(1).  
Two different immunization regimens were used to evaluate the efficacy of the 
AaMLAP-DNA immunization construct(1).  The AaMLAP-DNA immunization 
construct(1) was administered to mice by injection (i.m.), or by delivering the vaccine 
(i.d.) via gene gun particle bombardment.  A summary of all immunization constructs and 
immunization regimens is presented in Table 2.1 
Production of the immunization construct.  
All work outlined in this section is unpublished and was completed by Dr. Brian 
Foy.  To prepare the AaMLAP-DNA immunization construct(1), the AaMLAP gene was 
inserted into the pCDNA3.1(+) mammalian plasmid expression vector (Invitrogen, 
Carlsbad, CA, USA).  Briefly, complementary DNA (cDNA) was cloned via reverse 
transcriptase polymerase chain reaction (RT-PCR) from total RNA extracted from a pool 
of five mosquito midguts.  Cloning primers were constructed as follows:  a 5' primer was 
created containing the HindIII restriction site, Kozak sequence, ATG start codon and 18 
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nucleotides of gene specific sequence; a 3' primer was created containing the XbaI site, 
termination codon and 18 nucleotides of gene specific sequence.  The AaMLAP cDNA 
was cloned into the pCDNA3.1(+) vector, and the resulting AaMLAP-pCDNA3.1(+) 
plasmid was amplified in XL1 cells (Stratagene, La Jolla, CA). A high concentration 
stock was produced using the Qiagen Endotoxin-Free Giga-Prep kit (Qiagen, Valencia, 
CA) (Foy 2005- personal communication).   
The resulting AaMLAP-pCDNA3.1(+) plasmid was administered concurrently 
with a mouse interleukin-12 (mIL-12) adjuvant plasmid (Aldevron, Fargo, ND, USA), 
and the plasmid mixture will be referred to as the AaMLAP-DNA immunization 
construct(1).  The i.m. preparation of the AaMLAP-DNA immunization construct(1) was 
prepared as follows: Each dose contained 100 µg of the AaMLAP-pCDNA3.1(+)  
plasmid plus 100 µg of mIL-12 adjuvant plasmid  contained in 100 µl of sterile PBS.  
Control mice were immunized with 100 µl of the empty pCDNA3.1(+) plasmid  plus 100 
µl of the mIL-12 adjuvant plasmid contained in 100 µl of sterile PBS.   
Immunizations. 
Intra-muscular administration of the AaMLAP-DNA immunization construct(1). 
Drs. Foy, Douglas Brackney and Tereza Magalhaes performed the i.m. immunizations 
and mosquitocidal bioassays using the AaMLAP-DNA immunization construct(1).  The 
data are unpublished.  Two replicates of the experiment were conducted, and female 
Balb/c mice, 6-8 weeks old were used in both replicates.  In the first replicate, each 
experimental and control group consisted of four mice.  In the second replicate, each 
experimental and control group consisted of two mice.  Prior to immunization, each 
mouse was bled by nicking the tip of the tail with a razor blade and collecting blood into 
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a microtainer tube (BD Biosciences, San Jose, CA, USA) for serum separation.  Pre-
immune serum was pooled for each experimental group and stored at      -20°C.   
Mice were immunized a total of three times, with two weeks between each 
immunization.  Each immunization was administered by injecting 50 µl of the 
immunization construct into both the right and left hind quadriceps muscle. Two weeks 
following the final immunization, mice were restrained between wire mesh secured to a 
board by push pins, then placed into a cage of mosquitoes.  Immediately following the 
mosquito feed, mice were euthanized via carbon dioxide inhalation and terminally bled 
via cardiac puncture.  Blood was collected in serum separation microtainer tubes (BD 
Biosciences).  Serum was collected and stored at -20°C (Foy, B.D., personal 
communication, 2005).   
Administration of the AaMLAP-DNA immunization construct(1) via particle 
bombardment.  In this experiment, female Balb/c mice were immunized against 
AaMLAP via particle bombardment using the Helios Gene Gun (Biorad).  The plasmids 
used for immunization were the same as described in the previous section, and were 
kindly provided by Dr. Foy.  The experimental and control groups each consisted of 3 
total mice, however four weeks following initial immunization, one mouse from the 
control group died.    
Immunization doses were prepared as follows.  Immunization plasmids (either 
AaMLAP-pCDNA3.1(+) or the empty pCDNA3.1(+) plasmids were co-precipitated with 
the mIL-12 plasmid onto 1 μm gold beads (BioRad, Hercules, CA, USA) according to the 
manufacturer's instructions.  Briefly, 50 mg of gold beads and 100 μl of 0.05M 
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spermidine were combined in a microfuge tube, vortexed and then sonicated in an 
ultrasonic cleaner for 5 seconds.  One hundred μg of mIL-12 and 100 μg of AaMLAP-
DNA immunization construct-1 were added to the gold beads and vortexed.  One hundred 
μl of 1M CaCl2 was added to the tube, drop wise, while periodically vortexing the tube.  
The mixture was incubated at room temperature for 10 minutes and then centrifuged at 
5000 x g for 30 seconds.  The supernatant was removed and discarded, and the pellet was 
washed with 1 ml of absolute ethanol.  The coated gold beads were then loaded onto gold 
coat tubing using the Tubing Prep Station (BioRad) according to the manufacturer’s 
instructions.  Unevenly coated tubing was discarded and the remaining tubing was cut 
into 1.3 cm cartridges.   Control vaccine cartridges were prepared with the empty plasmid 
vector and mIL-12 plasmids according to the procedure outlined above.  The amount of 
DNA per cartridge was estimated by combining a cartridge and 500 µl of TE buffer into a 
microfuge tube.  Gold beads were dislodged from the tubing by placing the tubes into an 
ultrasonic cleaner water bath.  Gold beads were pelleted by a brief centrifugation, and 
DNA was quantified using a Nanodrop UV spectrophotometer.  The estimate for total 
DNA per AaMLAP DNA vaccine construct-1 + mIL-12 was 0.5 μg of DNA per 
cartridge.  The control vaccine cartridges were estimated to contain 1.0 μg of DNA per 
cartridge.   
Prior to immunization, mice were bled from the tail vein, and blood was collected 
into serum separation microtainer tubes (BD Biosciences).  Blood was allowed to clot at 
4°C overnight.  Serum was separated by centrifugation at 7,500 x g in a microcentrifuge 
and then stored at -20°C.   Mice received a total of two immunizations via intradermal 
particle bombardment, with two weeks in between the immunizations.  Each 
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immunization delivered a total of 1 μg of total plasmid DNA.   Prior to vaccine 
administration, the ventral side of the mouse was shaved.  Cartridges containing gold 
beads coated with the immunization plasmids were loaded into the Helios gene gun, 
which was positioned over the shaved immunization site.  Gold beads were dislodged 
from cartridges by a helium burst delivered at 200 pounds per square inch.  Six weeks 
after the second immunization, mice were restrained (described above), and were then 
placed into a cage of mosquitoes.  Immediately following the mosquito feed, mice were 
anesthetized using a Ketamine/Xylazine cocktail, bled via cardiac puncture and 
euthanized via cervical dislocation.   Blood was placed into serum separation tubes and 
serum was collected as described above. 
Production of a recombinant AaMLAP-SINV virus, and its use in an AaMLAP 
DNA: prime-alphavirus-boost immunization regimen. 
Production of the recombinant AaMLAP-SINV virus. 
Construction of the AaMLAP-SINV infectious clone. The Sindbis virus (SINV) 
vector used to generate the recombinant AaMLAP-SINV vaccine was the 5' double-
subgenomic SINV,  5'dsMRE16, which contains a double subgenomic promoter and 
multiple cloning site (Myles et al. 2003, Foy et al. 2004).  Gene specific primers for 
AaMLAP were designed to facilitate cloning of the gene into the 5’dsMRE16 plasmid 
vector by incorporating the NotI restriction recognition sequence on both the forward 
primer (AaM-SINV-Fwd) and reverse primer (AaM-SINV-Rev).  Additionally, a start 
codon was incorporated into the AaM-SINV-Fwd primer, and a stop codon was 
incorporated into the AaM-SINV-REV codon.  Primer sequences are reported in Table 
2.2.   
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A full-length AaMLAP amplicon, flanked by the NotI restriction recognition 
sequence at the 5’ and 3’ end was generated via PCR using the AaM-SINV-Fwd primer, 
the AaM-SINV-Rev primer amplicon and 500 ng of the purified AaMLAP-DNA 
immunization construct-1 plasmid as template DNA.  The PCR reaction consisted of: 50 
μl of 2X MasterMix containing Taq Polymerase (Promega, Madison, WI), 1 μl of 
forward primer at a 10 μM concentration, 1 μl of reverse pimer at a 10 μM concentration, 
and ultra pure water added to reach the final reaction volume of 100 µl.   The product was 
amplified using the following program on an MJ Research thermal cycler: 1 cycle of 
95°C for 5 minutes, 35 cycles of 95°C for 30 seconds, 55°C for 1 minute, 72°C for 60 
seconds, followed by a 10 minute extension step at 72°C.  After verifying the presence of 
a single 1.1 kilobase pair (kb) PCR product by agarose gel electrophoresis, the 
amplification product was purified using the QIAGEN PCR purification kit according to 
the manufacturer's instructions (Qiagen).  The amplification product was inserted into the 
5’dsMRE16 infectious clone, and proper orientation and DNA sequence were confirmed 
by DNA sequencing.  
 Production of recombinant AaMLAP-5'dsMRE16 virus.   Recombinant AaMLAP-
5'dsMRE16 virus particles were produced using an in vitro transcription system (Olson et 
al. 2000).  Briefly,  5 μg of the AaMLAP-5'dsMRE15 infectious clone was linearized 
using the restriction endonuclease AscI (New England Biolabs, Ipswich, MA, USA), and 
then digested with Proteinase K (Ambion, Austin, TX, USA) overnight at 37°C.  The 
reaction was extracted with cold saturated phenol, extracted once more using 24:1 
chloroform:isoamyl alcohol, and then precipitated using 3M sodium acetate (pH 5.2) and 
ethanol.  Linearized DNA was pelleted by centrifugation at 15,000 x g at 4°C in a 
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microcentrifuge, resolubilized in nuclease free water and quantified using a Beckman 
spectrophotometer (Beckman-Coulter, Brea, CA, USA).  The following in vitro 
transcription reaction was used to generate positive sense single stranded RNA: 1 μg of 
linear plasmid, 10 μl of a 75 mM mix of ribonucleotid triphosphates (rNTPs), 1.5 μl of 
1mM m7 -G(5')ppp(5')G cap analog, 5 μl of 5X transcription buffer, 40 units of SP6 
polymerase (Ambion) and nuclease free water to a final volume of 50 μl was incubated at 
39°C for one hour. After completion of the transcription reaction 25 μl of the resulting 
product was electroporated into 4 x 106 C6/36 cells by pulsing the cells at: 250 V, 25 Ω 
and 550 μF.  Cells were grown for one week, and then cells and supernatant were 
collected.  The virus was passaged once more in C6/36 cells, titrated and stored in 1 ml 
aliquots at -80°C. 
Immunizations.  
The DNA prime-virus-boost vaccination utilized the AaMLAP DNA-
immunization construct(1) and the recombinant AaMLAP-SINV described above.  A 
5'dsMRE16 virus containing enhanced green fluorescent protein (SINV-GFP) was used 
as a control virus.  The control and experimental groups consisted of five female Balb/c 
mice, aged 5-8 weeks at the time of the first immunization.   Prior to immunization, mice 
were bled by nicking the tail vein with a razor blade, and pre-immune serum was 
collected as described above.  The immunization regimen consisted of three i.m. DNA 
immunizations as described above, followed by one subcutaneous (s.c) injection using 
the recombinant 5’ dsMRE16 viruses.  Mice were injected with 103 plaque forming units 
of the virus contained in 100 µl of sterile PBS.  Two weeks following inoculation with 
virus, mice were restrained as described above, and placed into a cage of mosquitoes.  
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After the feed mice were anesthetized using a Ketamine/Xylazine cocktail and processed 
as described above.   
Production and administration of the AaMLAP-DNA immunization construct(2). 
Additional experiments utilizing the AaMLAP-DNA immunization construct-1 
were planned, so the plasmid was re-propagated by electroporating the plasmid into XL-1 
cells.  A high concentration stock was generated using an endotoxin-free gigaprep 
(Qiagen).  The newly purified plasmid and the original plasmid were submitted for DNA 
sequencing, which revealed an incomplete start codon in both plasmids.  The original 
sequencing data for the AaMLAP DNA immunization construct-1 was not available; 
therefore cDNA of AaMLAP was re-cloned and ligated into the pCDNA3.1(+)-TOPO 
DNA immunization vector (Invitrogen).   The pCDNA3.1(+)-TOPO plasmid is identical 
in sequence to the pCDNA3.1(+) vector used to generate AaMLAP DNA immunization 
construct-1, but does not require the use of restriction endonucleases and was chosen to 
simplify the cloning process.  
  Production of the immunization construct. 
 Aedes aegypti HWE mosquitoes were blood fed on defimbrinated sheep blood 
(Colorado Serum Company, Denver, CO, USA) through an artificial membrane feeder 
(Lillie Glassblowers, Smyrna, GA, USA).  A pool of fully engorged mosquitoes was 
retained in a 500 ml cardboard container covered with organdy fabric, with access to 
water and raisins.  Twenty-four hours following the blood meal, midguts were dissected 
from five mosquitoes and pooled.  Total RNA was harvested using Trizol (Invitrogen) 
according to the manufacturer’s instructions.  The AaMLAP cDNA was cloned via the 
RT-PCR procedure described above using the gene specific primers AaM-pCDNA Fwd 
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and AaM-pCDNA Rev.  Sequences for the primers are reported in Table 2.2.  The 
forward primer contained the Kozak sequence (ACC) followed by the start codon (ATG).  
Following verification of a single 1.1 kb PCR product, the PCR product was cloned into 
the pCDNA3.1(+)-TOPO plasmid according to the manufacturer's instructions.  
Chemically competent, TOP10, E. coli cells (Invitrogen) were transformed with the 
ligation reaction and then plated onto LB-Amp agar.  Individual colonies were grown in 
LB-Amp broth.  Plasmids were purified using the Qiagen Miniprep kit (Qiagen), and then 
sequenced.  After confirming proper gene insertion orientation and open reading frame, a 
high concentration stock was produced using the Qiagen Endotoxin-Free Giga-Prep Kit 
(Qiagen), according to the manufacturer’s instructions. The plasmid was reconstituted in 
sterile PBS and stored at  -20˚C.  
Immunizations. 
The AaMLAP-DNA immunization construct(2) was administered, i.m., using the 
same procedure described for the AaMLAP-DNA immunization construct(1).  Female 
Balb/c mice, aged 6-8 weeks at the time of immunization were used for the experiment, 
and the experimental and control groups each consisted of five mice.  Prior to 
immunization, mice were bled by nicking the tail vein with a razor blade, and serum was 
collected as described above.   
Production and administration of a recombinant AaMLAP protein immunization 
construct. 
Production of the immunization construct.  
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The pBAD/TOPO ThioFusion expression vector , which will be abbreviated as 
pBAD, (Invitrogen) was selected because it contains a C-terminal polyhistidine tag for 
purification, a V5 epitope for identification, and an inducible promoter (araBAD), 
allowing for inducible expression of the protein in the presence of L-arabinose (L-ara).   
 Cloning of AaMLAP into the pBAD plasmid.  The AaMLAP sequence was 
amplified by RT-PCR using total mosquito RNA from 24-hour post blood fed female Ae. 
aegypti mosquitoes as a template, and the gene specific primers AaMpBAD Fwd and 
AaMpBAD Rev.  Sequences for the primers are reported in Table 2.2.  The forward 
primer contained the start codon.  The stop codon was omitted from the reverse primer to 
allow translation of the polyhistidine tag and V5 epitope.  Total RNA was extracted from 
mosquitoes using Trizol (Invitrogen) according to the manufacturer's instructions.  
Complementary DNA (cDNA) was synthesized as follows:  500 ng of total RNA was 
incubated with 1 μl of 10 mM dNTPs, 1 μl of reverse primer at a 10 mM concentration 
and 9 μl of nuclease free water for 5 minutes at 65°C.  The reaction was subsequently 
placed onto ice, and the following reagents were added: 4 μl of first strand buffer, 2 μl of 
0.1M DTT, 1 μl of RNaseOUT, and 1 μl of Superscript II reverse transcriptase 
(Invitrogen).  The reaction was heated to 50°C for 1 hour, and then heated at 70°C for 15 
minutes.   
The resulting cDNA, AaMpBAD fwd primer and AaMpBAD rev primer were 
then used to generate an AaMLAP amplicon via PCR as described above. Following 
verification of a single 1.1 kb PCR product, the PCR product was cloned into the pBAD 
plasmid according to the manufacturer's instructions.  Chemically competent TOP10 E. 
coli cells (Invitrogen) were transformed with the ligation reaction and then plated onto 
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LB- agar containing 100 µg/ml of ampicillin (LB-Amp).  Individual colonies were grown 
in LB-Amp broth.  Plasmids were purified using the Qiagen miniprep kit (Qiagen), and 
then sequenced to verify proper orientation of the insert, presence of the start codon and 
the proper open reading frame to allow expression of the AaMLAP protein, polyhistidine 
tag and V5 epitope.   
 Expression of recombinant AaMLAP.  After verifying that the AaMLAP gene was 
properly inserted into the pBAD vector, the plasmid was grown in TOP10 E. coli cells 
(Invitrogen), which were grown in a shaking incubator at 37°C to mid-log phase, as 
determined by an optical density of 0.5 read at a wavelength of 600 nm (OD600). Once the 
cultures reached an OD600 of 0.5, L-ara was added at a final concentration of 0.02%.  The 
0.02% L-ara concentration was determined to be the optimal concentration for inducing 
protein production by testing multiple concentrations of the L-ara.  Bacterial cells were 
harvested by centrifugation in a table top centrifuge at 6,000 x g for 5 minutes at 25°C, 
supernatant was removed and the pellets were frozen overnight at -20°C.  
 Detection of recombinant AaMLAP.  After being held overnight  at -20°C, the 
bacterial cell pellet was resuspended in 100 μl of 2X sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer, heated to 90°C for 5 
minutes, then centrifuged at 15,000 x g for 15 minutes at room temperature.  To confirm 
recombinant protein was expressed from the AaMLAP-pBAD plasmid, 10 μl of the 
resulting bacterial lysate was loaded onto a 10% SDS-PAGE gel, which was run in 
duplicate.  Gels were run at 200V using a BioRad Mini-Protean II cell (BioRad) under 
reducing conditions.  One of the SDS-PAGE gels was submerged in coomassie brilliant 
blue stain [0.25% coomassie brilliant blue (w/v), 50% methanol (v/v) and 10% glacial 
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acetic acid (v/v)] for one hour.  The gel was de-stained using a solution of 5% methanol 
and 7.5% glacial acetic acid.   The remaining gel was subjected to western blotting 
analysis.  Proteins contained in the SDS-PAGE gel were transferred to a polyvinylidene 
fluoride (PVDF) membrane, which was blocked for one hour at room temperature using 
5% non-fat dry milk diluted in phosphate buffered saline containing 0.1% tween-20 
(PBST).  The membrane was washed three times with PBST for 5 minutes, and then 
incubated with the an anti-V5-horseraddish peroxidase (HRP) antibody (Invitrogen), 
diluted 1:5000 in blocking buffer, for one hour at room temperature.  The membrane was 
then washed three times with PBST, developed with the ECL Plus Western Blotting 
Detection Kit (GE Health Sciences, Arlington Heights, IL, USA), exposed to X-ray film 
and developed using an automatic film developer (Kodak, Rochester, NY, USA). 
  Efforts to purify the recombinant protein expressed from the pBAD-AaMLAP 
plasmid failed to yield sufficient quantities of recombinant protein for immunizations, so 
SDS-PAGE gel strips containing the protein were used for immunizations.  Five 10 ml 
cultures containing E. coli transformed with the pBAD-AaMLAP plasmid were grown as 
described above and induced with L-ara at a concentration of 0.02%.  Bacterial cells were 
pelleted as described above, resuspended in 100 μl of 2X SDS-PAGE loading buffer, 
heated to 90°C for five minutes, and then centrifuged at 15,000 x g for 15 minutes in a 
microcentrifuge at room temperature.  For each dose of the recombinant AaMLAP 
protein vaccine, 20 μl of the lysate was loaded into the lane of a 10% SDS-PAGE gel and 
run under denaturing and reducing conditions.   Three bovine serum albumin (BSA) 
standards, 1.0, 2.5, and 5 μg per well were run on each SDS-PAGE gel.   The SDS-PAGE 
gel was stained with coomassie brilliant blue and de-stained as described previously, then 
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washed in sterile deionized water.  The region of the gel containing the AaMLAP 
recombinant protein was excised using a razor blade, and the quantity of recombinant 
AaMLAP protein in each lane was estimated to be 2.5 μg by visually comparing the 
AaMLAP band to the BSA standards.  To prepare the AaMLAP polyacrylamide gel 
slurry used for immunizations, five gel strips, each containing the excised AaMLAP 
protein, were combined into a ceramic mortar and ground under liquid nitrogen to a fine 
powder.  The powder was resolubilized in 500 μl of sterile PBS, which was subsequently 
passed through an 18 gauge needle.  Each immunization dose consisted of 100 μl of the 
PBS-gel strip slurry, and was estimated to contain 2.5 μg of recombinant AaMLAP 
protein.  Control vaccine doses consisted of 2.5 µg of BSA, which was run on an SDS-
PAGE gel and excised according to the methods described above.                                                              
Immunizations. 
Balb/c mice, aged 5-8 weeks at the time of first immunization, were used in this 
study. Prior to immunization, mice were bled by nicking the tail vein with a razor blade, 
and pre-immune serum was processed as described above.  Mice were given either three 
(n= 2 mice) or four (n=3 mice) immunizations with the AaMLAP polyacrylamide gel 
slurry, with two week intervals between each immunization.  For each immunization, 
mice were injected (s.c.) with 100 µl of the AaMLAP-polyacrylamide gel slurry.  Two 
weeks after the final immunization, mice were restrained as described above, and placed 
into a cage of mosquitoes.  After the blood feed mice were anesthetized using a 
Ketamine/Xylazine cocktail and processed as described above.   
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Mosquitocidal bioassay.  
Immunization efficacy was assessed using the following bioassay.  One day prior 
to blood feeding on immunized mice, two to three day old adult Ae. aegypti HWE 
mosquitos were transferred to 4 L cages.  Prior to the blood feed, mosquitoes were 
deprived of sugar and water for 24 and 12 hours, respectively.  Each live mouse was 
restrained as described above. Once immobilized, the mouse was placed into a cage of 
mosquitoes.  A separate cage of mosquitoes was used for each mouse.  After one hour, 
mice were removed, bled and euthanized (described above).  Mosquitoes were cold-
anesthethized in a refrigerator, placed onto a glass Petri dish maintained on ice, and 
sorted for the presence of a blood meal.  Only fully engorged mosquitoes were retained 
for survival analysis. Mosquitoes were retained for seven days following the blood feed, 
and mortality was recorded every day.  
Statistical analysis.  
For each experimental group, mosquito mortality tabulated seven days after 
feeding on each mouse was compared individually with all other mice using a Fisher’s 
exact test, with the significance level set at P < 0.05.  If no significant within-group 
differences in mosquito survivorship were observed, data within groups were pooled and 
significant differences in mosquito survival between the immunized and control group 
were analyzed using a Fisher’s exact test.    
Antibody detection via western blotting. 
 To test for antibodies against AaMLAP, pre and post-immunization serum from 
all immunization regimens, and Schistosoma japonicum cathepsin-D antiserum (kindly 
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provided by Dr. Paul Brindley) were probed against mosquito homogenate and the 
bacterial lysate containing the recombinant AaMLAP protein (described above).   
Protein preparation, separation and transfer.  
The mosquito homogenate was prepared by first blood feeding Ae. aegypti HWE 
mosquitoes on defimbrinated sheep blood.  Given that peak AaMLAP protein production 
occurs 42 hours following a blood feed (Cho and Raikhel 1992), whole mosquito 
homogenates were prepared by grinding a pool of ten 42 hour post-blood fed mosquitoes 
into 100 µl of SDS-PAGE sample buffer, boiling the mixture for five minutes, then 
pelleting insoluble material by centrifugation at 700 x g for three minutes.  One mosquito 
equivalent was estimated to be 10 µl of the prepared homogenate. One mosquito 
equivalent was loaded into each well of a 10% SDS-PAGE gel.   
The recombinant AaMLAP protein was produced in E. coli cells according to the 
methods described above, and 10 µl of the bacterial lysate was loaded into each well of a 
10% SDS-PAGE gel. 
Proteins were separated using SDS-PAGE electrophoresis under denaturing and 
reducing conditions, transferred to a PVDF membrane which was blocked in 5% non-fat 
dry milk in PBST for one hour at room temperature.  The membrane was cut into strips, 
with each strip corresponding to a well from the SDS-PAGE gel. 
Antibody detection. 
To absorb antibodies developed against E.coli proteins that were included with 
SDS-PAGE gel strip immunization, prior to western blotting, post-immune mouse sera 
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from the recombinant protein immunizations were incubated with beads coated with E. 
coli lysate (Pierce Protein Research Products, Rockford, IL, USA).  
 For each immunization regimen, a pool of post immune serum was created by 
combining 2 µl of serum from each mouse into an microfuge tube, and then mixing the 
serum by pipetting.  A pre-immune serum pool was produced by combining 2 µl from all 
mice into a microfuge tube and mixing the serum by pipetting.   Serum was then diluted 
to a working concentration of 1:250 in blocking buffer, and then incubated on a blocked 
PVDF membrane strip gel strip containing either the mosquito homogenate or 
recombinant AaMLAP protein.  The PVDF membrane strips were then washed three 
times with PBST for 15 minutes, and incubated for one hour at room temperature with a 
horseradish peroxidase (HRP) conjugated polyclonal rabbit anti-mouse secondary 
antibody (Abnova, Walnut, CA, USA) diluted 1:5000 in blocking buffer.  The PVDF 
membrane strips were washed three times with PBST for 15 minutes, and finally 
developed using the Vector VIP Substrate (Vector laboratories).  
Evaluation of rabbit AgGluCl antiserum following oral ingestion in an in vitro blood 
meal.   
An in vitro feeding assay was used to evaluate the effect of rabbit AgGluCl anti-
serum on the survival of Ae. aegypti.  One ml of human blood preserved in 3.2% sodium 
citrate was centrifuged at 7,500 x g in a microcentrifuge.  Serum and the buffy coat were 
removed, and the remaining erythrocytes were washed twice in 1 ml of sterile PBS.  A 
volume of rabbit AgGluCl antiserum (kindly provided by Dr. Brian Foy) equivalent to 
the volume of discarded human serum was mixed with the washed erythrocytes.  The 
resulting mixture of rabbit serum and human erythrocytes was placed into a water-
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jacketed glass bell feeder (Lillie Glass Blowers) which had been sealed with hog gut 
sausage casing.   The membrane feeder was warmed to and maintained at 37°C using a 
circulating water pump for the duration of the feed.  Washed erythrocytes re-constituted 
with pre-immune rabbit serum and heat inactivated normal rabbit serum (Sigma-Aldrich, 







Table 2.1: Summary of Immunizations against the AaMLAP 
Description of Immunization Immunization Regimen; Route of administration (frequency) 
1. DNA immunization AaMLAP- DNA immunization construct(1); i.m. (3X) OR i.d. (2X) 
  
  AaMLAP- DNA immunization construct(2); i.m. (3X)
   
2. DNA immunization prime-
alphavirus-boost 
AaMLAP- DNA immunization construct(1); i.m. (2X) followed by AaMLAP-SINV; s.c. (1X) 
   






Table 2.2: Primers used to clone AaMLAP into different plasmid expression vectors 
Primer name Primer Sequencea
AaM-SINV Fwd 5' -ATT GTT GCG GCC GCA CCA TGC TAA TTA AAT CAA- 3’ 
AaM- SINV Rev 5' -ATT GTT GCG GCC GCA CCT TAG ACA GCA GTG GCA AAT CC- 3'. 
AaM- pBAD Fwd 5' - ATG CTA ATT AAA TCA ATT ATT GCC CTG GTT TGC- 3' 
AaM- pBAD Rev 5' -GAC AGC AGT GGC AAA TCC AAC GCT- 3' 
AaM- pCDNA Fwd 5’- ACC ATG CTA ATT AAA TCA ATT ATT G- 3’ 
AaM-pCDNA Rev 5’ – TTA GAC AGC AGT GGC AAA TCC 3’ 
a The NotI restriction recognition sequence is denoted in bold font. Start codons sequences are denoted 
by text underlined once. Stop codons are denoted by text underlined twice, and the Kozak recognition 
sequence is denoted in italicized font. 




Mosquitocidal bioassay of the AaMLAP-DNA immunization construct(1) 
immunization regimen.  
 Intramuscular administration.  Two experimental replicates were conducted, and 
in both experimental replicates, mosquito survival was reduced after feeding on mice 
immunized (i.m.) with the AaMLAP-DNA immunization construct(1).   
In the first experimental replicate, analysis of mosquito survival, by mouse, within 
treatment groups did not reveal significant differences in either the control group (Fig 
2.1A) or the group that had received three injections (i.m.) with AaMLAP-DNA 
immunization construct(1) (Figure 2.1B).  Mosquito survival data within treatment 
groups were pooled and analyzed.  After seven days, the percentage of mosquitoes 
surviving after feeding on mice injected three times with the AaMLAP-DNA 
immunization construct(1) was significantly reduced,  1.23 fold, relative to control- 
immunized mice (P<0.0001) (Figure 2.1C). 
In the second experimental replicate, analysis of mosquito survival, by mouse, 
within treatment groups did not reveal significant differences in either the control group 
(Figure 2.2A) or in the group that had received three injections (i.m.) with the AaMLAP-
DNA immunization construct(1) (Figure 2.2B).  Mosquito survival data within treatment 
groups were pooled and analyzed.  After seven days, the percentage of mosquitoes 
surviving after feeding on mice injected three times with the AaMLAP-DNA 
immunization construct(1) was marginally reduced relative to control immunized mice 
(P=0.048) (Figure 2.1C).  
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 Intra-dermal administration.  Following i.d. immunization with the AaMLAP-
DNA immunization construct(1), mosquito survival was reduced after feeding on two of 
the mice (mice 1 & 2), but was not reduced after blood feeding on mouse 3 (Figure 
2.3A).  Mosquito survival did not differ significantly between mouse 1 and mouse 2, 
however mouse 3 differed significantly from both mouse 1 and mouse 2 (P = 0.011 and P 
= 0.036, respectively).   One of the control immunized mice died prior to the mosquito 
feed; however, of the remaining two mice, there were not significant within group 
differences in mosquito survival after blood feeding (Figure 2.3B).   A cumulative, 
between group, comparison of mosquito survival was made by omitting the data from 
mouse-3 in the AaMLAP immunization group, and then pooling the data within groups.  
The resulting comparison revealed that mosquito survival was significantly reduced after 
blood feeding on the mice immunized (i.d.) with the AaMLAP-DNA immunization 
construct-1 when compared to control immunized mice (P=0.017) (Figure 2.3 C). 
 














































































Figure 2.1: Survival of mosquitoes after blood feeding on mice immunized (i.m) with the AaMLAP-DNA-immuzation 
construct(1) (replicate 1).  Two weeks following the final immunization, all mice were fed upon by Ae. aegypti.  Percent 
survival of mosquitoes blood fed on each mouse that had been immunized with  pCDNA3.1(+) plasmid only + mIL-12 (A) or 
AaMLAP-DNA immunization construct(1) (B) are shown.  Within group comparisons of mosquito mortality by mouse revealed 
no significant differences, and data were pooled (C).  Mortality of mosquitoes that fed upon mice immunized with the AaMLAP-
DNA immunization construct(1) was significantly greater (P<0.001) than mortality observed in mosquitoes fed on control 
immunized mice. n= the total number of blood fed mosquitoes.  
C. 
B. A. 









































































Figure 2.2: Survival of mosquitoes after blood feeding on mice immunized (i.m) with the AaMLAP-DNA-immuzation 
construct(1) (replicate 2).  Two weeks following the final immunization, all mice were fed upon by Ae. aegypti.  Percent 
survival of mosquitoes blood fed on each mouse that had been immunized with pCDNA3.1(+) plasmid only + mIL-12 (A) or 
the AaMLAP-DNA immunization construct(1) (B) are shown.  Within group comparisons of mosquito mortality by mouse 
revealed no significant differences, and data were pooled (C).  Mortality of mosquitoes that fed upon mice immunized with the 
AaMLAP-DNA immunization construct(1) was marginally greater (P<0.0485) than mortality observed in mosquitoes fed on 
control immunized mice. n= the total number of blood fed mosquitoes.  
C. 
A. B. 













































































Figure 2.3: Survival of mosquitoes after blood feeding on mice immunized (i.d.) with the AaMLAP-DNA-immuzation construct(1).  
Two weeks following the final immunization, each mouse from the experimental and control group was fed upon by Ae. aegypti.  Percent 
survival of mosquitoes blood fed on each mouse that had been immunized with (A) pCDNA3.1(+) plasmid only + mIL-12 (B) AaMLAP-
DNA immunization construct-1 + mIL-12 are shown.  Within group comparisons of mosquito mortality by mouse revealed no significant 
differences between control mice.  In the AaMLAP immunization group, mosquito mortality after feeding on mouse 3 was significantly 
lower than mice 1 and 2 (P<0.05).  Mosquito mortality after feeding on AaMLAP mouse 3 did not differ significantly from either of the 
control mice.   (C) Mortality of mosquitoes that fed upon AaMLAP mice 1 and 2 mice immunized with the AaMLAP-DNA immunization 
construct 1 was significantly lower (P=0.017) than mortality observed in mosquitoes fed on control immunized mice. n= the total number 
of blood fed mosquitoes.  
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Mosquitocidal bioassay of the AaMLAP-DNA prime-alphavirus-boost 
immunization regimen.  
 Analysis of mosquito survival, by mouse, within treatment group did not reveal 
significant differences in either the control group (Figure 2.4A) or in the group treated 
with the AaMLAP-DNA-prime-alphavirus-boost immunization regiment (Figure 2.5B). 
Mosquito survival data within treatment groups were pooled and analyzed.  No 
significant (P>0.05)differences in mosquito mortality were observed between mosquitoes 
which had fed on mice immunized via the AaMLAP-DNA prime-alphavirus-boost 








Figure 2.4: Survival of mosquitoes after blood feeding on mice treated with the AaMLAP-DNA: prime-alphavirus-
boost immunization regimen. Two weeks after the inoculation with recombinant SINV, all mice were fed upon by Ae. 
aegypti.  Percent survival of mosquitoes blood fed on mice treated with the control immunization regimen (A)  and mice 
treated with the AaMLAP-DNA-prime-alphavirus boost immunization regimen (B) are shown.  Within group comparisons of 
mosquito mortality by mouse revealed no significant differences, and data were pooled (C).   No significant difference 
(P>0.05) in mosquito mortality was observed between mosquitoes that fed on control immunized mice and mice immunized 
with the AaMLAP-DNA: prime-alphavirus-boost regimen.
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Mosquitocidal bioassay of the AaMLAP-DNA immunization construct(2) 
immunization regimen.  
 Analysis of mosquito survival, by mouse, within treatment groups did not reveal 
significant differences in either the control group (Figure 2.5A) or the group that received 
three injections (i.m.) of the the AaMLAP-DNA immunization construct(2) (Figure 
2.5B).  Mosquito survival data within treatment groups were pooled and analyzed. No 
significant difference (P>0.05) in mosquito mortality was observed between mosquitoes 
which had fed on mice immunized with the AaMLAP-DNA immunization construct(2) 
when compared to the corresponding control immunized mice (Figure 2.5C). 
 


















































































Figure 2.5: Survival of mosquitoes after blood feeding on mice immunized (i.m) with the AaMLAP-DNA-immuzation 
construct(2).  Two weeks following the final immunization, each mouse from the experimental and control group was fed 
upon by Ae. aegypti.  Percent survival of mosquitoes blood fed on each mouse that had been immunized with (A) 
pCDNA3.1(+) plasmid only + mIL-12 (B) AaMLAP-DNA immunization construct(2) are shown.  Within group comparisons 
of mosquito mortality by mouse revealed no significant differences, and data were pooled (C).  No significant difference 
(P>0.05) in mosquito mortality was observed between mosquitoes that fed on control immunized mice and mice immunized 
with the AaMLAP-DNA immunization construct(2). 
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Expression of recombinant AaMLAP protein in the pBAD expression system. 
 The AaMLAP protein is approximately 40 kilodaltons (kDa) in size (Cho and Raikhel 
1992).  The polyhistidine tag and V5 epitope increase the size of the protein by 16 kDa.  
Therefore, the expected size of the recombinant AaMLAP protein, expressed in the pBAD 
expression system, is approximately 56 kDa.  Expression of the recombinant AaMLAP protein in 
bacterial cultures was confirmed via Coomassie brilliant blue staining and Western blot.  A 56 
kDa protein was observed in bacterial lysates from cultures that had been treated with L-ara, but 
was not observed in the control bacterial lysate that was not treated with L-ara (Figure 2.6A).  A 
Western blot using the anti-V5-HRP antibody revealed that a 56 kDa protein containing a V5 
epitope was expressed in all L-ara treated cultures, except at the lowest concentration tested 
(0.00002%). No protein containing a V5 epitope was detected in the non-induced control culture 
(Figure 2.6B).  





















Figure 2.6. Coomassie brilliant blue staining and Western blotting analysis of recombinant AaMLAP 
protein expressed with the pBAD expression system.  E. coli cells transformed with the AaMLAP-pBAD 
plasmid were induced with varying concentrations of L-ara.   Cell lysates were prepared, and 20 µl from each 
lysate was loaded onto 10% SDS-PAGE gels, which were stained with Coomassie brilliant blue (A) or 
probed with an anti-V5 antibody via Western blotting analysis (B).  Known quantities of BSA (2.5 µg , 5.0 
µg, 7.5 µg) were included in Coomassie brilliant blue staining to allow for relative quantitation of 
recombinant AaMLAP.  The Coomassie brilliant blue-stained  recombinant protein is shown in the box. 
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Mosquitocidal bioassay of the recombinant AaMLAP protein immunization 
regimen. 
 To evaluate whether immunization with the AaMLAP polyacrylamide gel slurry 
(described above) could elicit a mosquitocidal response, mice were injected (s.c.), either 
three or four times.  Control immunizations were administered by injecting mice (s.c.), 
either three or four times, with the polyacrylamide-BSA gel slurry (described above).  
 Mosquitocidal bioassay of mice immunized three times with the polyacrylamid-
AaMLAP slurry: Analysis of mosquito survival, by mouse, within treatment groups did 
not reveal significant differences in either the control group (Figure 2.7A) or the  group 
which received three injections of the polyacrylamide-AaMLAP gel slurry (Figure 2.7B).  
Mosquito survival data within treatment groups were pooled and analyzed.  After seven 
days, the percentage of mosquitoes surviving after feeding on mice injected three times 
with the polyacrylamide-AaMLAP gel slurry was significantly reduced ,1.11-fold, 

































Figure 2.7: Survival of mosquitoes after blood feeding on mice immunized three times (s.c.) with the recombinant 
AaMLA_-polyacrylamide gel slurry.  Two weeks following the final immunization, all mice were fed upon by Ae. aegypti.  
Percent survival of mosquitoes blood fed on each mouse that had been immunized three times with the polyacrylamide BSA 
gel slurry (A) or the AaMLAP-polyacrylamide gel slurry (B). Within group comparisons of mosquito mortality by mouse 
revealed no significant differences, and data were pooled.  Mortality of mosquitoes that fed upon mice immunized with the 
recombinant AaMLAP protein was significantly greater (P=0.034) than mortality observed in mosquitoes fed on control 
immunized mice (C).  n= the total number of blood fed mosquitoes. 















































B.  A.  
   
83 
 
 Mosquitocidal bioassay of mice immunized four times with the polyacrylamid-
AaMLAP slurry: Analysis of mosquito survival, by mouse, within the group of mice 
immunized four times (s.c.) with the polyacrylamide AaMLAP gel slurry did not reveal 
significant differences in mosquito survival among mice (Figure 2.8B).  Analysis of 
mosquito survival, by mouse, within the control group revealed that mosquito survival 
after blood feeding on control mouse-1 was significantly lower than control mouse-2 and 
control mouse-3 (P<0.001) (Figure 2.8A).  Mosquito survival after feeding on control 
mouse-1 was also significantly lower than each of the mice immunized with the 
AaMLAP polyacrylamide gel slurry (P<0.05), and was therefore treated as an outlier and 
removed from analysis.  Mosquito survival data within groups were pooled and analyzed.  
After seven days, the percentage of mosquitoes surviving after feeding on mice injected 
four times with the polyacrylamide-AaMLAP gel slurry was significantly reduced,1.08-
fold, relative to control-immunized mice (P=0.031) (Figure 2.8C). 
 The cumulative percent mortality of mosquitoes fed on mice immunized three 
times or four times with the polyacrylamide gel-AaMLAP protein slurry was 1.11-fold 
and 1.08-fold lower, respectively, compared to the corresponding control groups.  The 
mosquitocidal bioassays for the two immunization regimens were completed using 
different cohorts of mosquitoes, and were not completed concurrently.  Thus, differences 
in mosquito survival between the two different immunization regimens were not 
subjected to statistical analysis. 
 











































































Figure 2.8: Survival of mosquitoes after blood feeding on mice immunized four times (s.c.) with the recombinant 
AaMLAP polyacrylamide gel slurry.  Two weeks following the final immunization, all mice were fed upon by Ae. aegypti.  
Percent survival of mosquitoes blood fed on each mouse that had been immunized four times with the polyacrylamide BSA 
slurry (A) or the polyacrylamide AaMLAP gel surry (B).  In the control immunized group, mosquito mortality after feeding on 
mouse 1 was significantly different than control mice 1 and 2 (P<0.001), and was omitted from cumulative analysis.  Within 
group comparisons of AaMLAP immunized mice revealed no significant differences in mosquito mortality, by mouse.  
Mortality of mosquitoes that fed upon mice immunized against AaMLAP was significantly lower (P=0.031) than mortality 
observed in mosquitoes fed on control immunized mice 2 and 3 (C).  n= the total number of blood fed mosquitoes. 
B.  A.  
C.  
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Detection of AaMLAP antibody from immunized mice. 
 The AaMLAP protein isolated from Ae. aegypti mosquitoes has a molecular mass 
of 40 kDa (Cho and Raikhel 1992).  Western blot analysis using whole mosquito 
homogenate did not detect anti-AaMLAP antibodies in the pre-immune serum pool or in 
post-immune serum pools from any of the immunization regimens. No cross-reactivity 
was observed between the S. japonicum cathepsin D anti-sera and the mosquito 
homogenate (Figure 2.10).  
 Efforts to remove anti-E.coli antibodies from the post-immune serum harvested 
from mice immunized with the AaMLAP polyacrylamide gel slurry were unsuccessful.  
When post-immune serum from mice immunized with the AaMLAP polyacrylamide gel 
slurry was probed against E. coli cell lysate from non-transformed E. coli cells, a band at 
approximately 56 kDa was observed (Figure 2.11A).   
To determine if post-immune serum from any of the immunization regimens 
would react with the recombinant AaMLAP protein produced in the pBAD expression 
system, serum was probed against a bacterial lysate prepared from E. coli cells 
expressing the recombinant AaMLAP protein.  An anti-V5 antibody was used to confirm 
expression of the protein.  Post-immune serum from mice immunized with the AaMLAP 
polyacrylamide gel slurry detected a band of similar molecular weight to that of the 
positive control.  Post-immune serum from mice immunized (i.m.) with the AaMLAP-
DNA immunization construct(1) and AaMLAP-DNA immunization construct(2) yielded 
a band at approximately 25 kDa, which was not the in the molecular weight range of the 
AaMLAP protein (Figure 2.11B).  The S. japonicum cathepsin-D antisera yielded a band 
of approximately 60 kDa, which was also not in the molecular weight range of the 
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AaMLAP protein (Figure 2.11B).  Post-immune serum from i.d. immunization with the 
AaMLAP-DNA immunization construct(1) and immunization from the AaMLAP-prime-
alphavirus boost immunization regimen did not yield distinct bands of any size (Figure 
2.11B).  







Figure 2.10. Reactivity of pre-and post-immune sera collected from immunized mice 
with whole mosquito homogenate.  Pre- and post-immune mouse serum and the S. 
japonicum cathepsin-D antiserum were probed against Ae. aegypti mosquito homogenate 
prepared from 42-hour post-blood fed mosquitoes. 





Figure 2.11.  Reactivity of pre-and post-immune sera collected from immunized mice with bacterial lysate.  Post-immune serum 
from all mice immunized with the polyacrylamide AaMLAP gel slurry was probed against E. coli lysate prepared from cells that had 
not been transformed with the AaMLAP-pBAD plasmid (A).  Pre- and post-immune mouse and the S. japoinicum cathepsin-D 
antiserum were probed against bacterial lysate prepared from E.coli cells that were expressing the AaMLAP protein.  Expression of 
the  recombinant AaMLAP protein was verified by probing the lysate with a commercial anti-V5 antibody as a positive control (B). 
B.  A.  
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Survival of Ae. aegypti mosquitoes after imbibing AgGluCl antiserum. 
 Twenty mosquitoes blood fed on blood containing the AgGluCl antiserum, 
however only one mosquito blood fed on the blood containing the pre-immune rabbit 
serum, and two mosquitoes blood fed on the blood containing normal rabbit serum.  After 
seven days, no mortality was seen in any of the mosquitoes which had imbibed a blood 
meal containing the AgGluCl antiserum or in mosquitoes which had imbibed blood 
containing normal rabbit serum.  The only mosquito which had imbibed blood containing 
the pre-immune rabbit serum died two days after blood feeding.  Due to exceptionally 
low sample sizes in the control groups, survival data from the groups were not subjected 
to statistical analysis. 
Discussion. 
 Mosquitocidal immunity has been demonstrated numerous times (Alger and 
Cabrera 1972, Hatfield 1988, Almeida and Billingsley 1998, 1999, Lal et al. 2001, 
Almeida and Billingsley 2002, Foy et al. 2003), yet only two specific mosquitocidal 
antigens, the Anopheles gambiae Mucin-1 protein (Foy et al. 2003), and the Aedes 
albopictus subolisin (Canales et al. 2009) have been described.   If mosquitocidal 
vaccines are ever to become a possible strategy for mosquito-borne disease, specific 
mosquitocidal antigens must first be identified.   The purpose of this research was to 
determine if the AaMLAP and AaGluCl anion channel could be immunologically 
targeted to induce mosquitocidal activity.  While we did observe a decrease in mosquito 
survival after feeding on certain AaMLAP-immunized mice, it remains unclear whether 
or not the AaMLAP is a mosquitocidal target.   
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 A reduction in Ae. aegypti mosquito survival was observed in three different 
experiments where mosquitoes had blood fed on mice that had been immunized (i.m. and 
i.d.) with the AaMLAP-DNA immunization construct(1).   These results are especially 
surprising because we discovered a deletion in the start codon in the AaMLAP-
pCDNA3.1(+) plasmid included in this immunization construct.  Examination of 
alternate open reading frames in the DNA plasmid revealed numerous other start codons 
(5’ATG 3’), which could have resulted in expression of a truncated AaMLAP protein or 
multiple other polypeptides.  We could have characterized any of the putative 
polypeptides and evaluated their ability to induce mosquitocidal immunity in mice, 
however, the reduction in mosquito survival was minimal, and we did not further explore 
these putative polypeptides.  It is unlikely that co-immunization with the pCDNA3.1(+) 
and mIL-12 plasmids is what resulted in a mosquitocidal immune response, as mosquito 
survival in control-immunized mice was not similarly reduced.   
Given the incomplete start codon in the AaMLAP-pCDNA3.1(+) plasmid, it is 
not surprising that serum collected from mice immunized with the AaMLAP-DNA 
immunization construct(1) did not yield a band within the expected molecular weight 
range (40 kDa) when probed against mosquito homogenate or bacterial lysate containing 
the recombinant protein expressed from the pBAD-AaMLAP plasmid.  However, an 
important caveat is that we did not have a positive control antiserum, thus we cannot 
conclude that the failure to detect antibody was not due to experimental error.   We 
included the S. japonicum cathepsin-D antiserum in western blotting analysis to 
determine if this serum could act as a positive control, however, it also failed to yield a 
band within the expected molecular weight range of the AaMLAP protein.  These 
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findings may not be extraordinarily surprising, as post-immune serum from mice 
immunized against the S. japonicum cathepsin-D aspartic protease failed to cross-react 
with homogenates prepared from S. mansonii (Chlichlia et al. 2002).  
No reduction was seen in mosquito survival after feeding on mice that had been 
immunized via the AaMLAP-DNA: prime-alphavirus-boost immunization regimen. 
These results are somewhat surprising, as the DNA immunization plasmid used in the 
AaMLAP-DNA:prime-alphavirus-boost immunization regimen was the same plasmid 
used to generate the AaMLAP-DNA immunization(1) construct.  One possible 
explanation for the lack of mosquitocidal response is that the SINV virions encoded in its 
subgenomic promoter were stronger immunogens than AaMLAP-DNA immunization 
construct(1).  If the mouse immune response was primarily directed against SINV 
antigens, then such a response could have had a dilution effect on the effector of 
mosquitocidal immunity seen in the previous experiments.  We made an attempt to 
quantify SINV antibody titers from all mice by a plaque-reduction neutralization test, 
however sufficient quantities of post-immune serum to optimize and trouble-shoot the 
assay were not available, therefore accurate titers could not be determined.   
 Post-immune serum from mice immunized with the AaMLAP-prime-alphavirus 
boost immunization regimen did not react with either the mosquito homogenate or 
bacterial lysate containing the recombinant protein expressed from the AaMLAP-pBAD 
plasmid.  Although alphavirus vectors are known to be high-level transient expression 
vectors (Atkins et al. 2008), we did not have a known anti-AaMLAP antiserum, and 
could not determine whether the AaMLAP protein was expressed by the alphavirus 
vector.  The failure of the post-immune serum to react with either the mosquito 
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homogenate or the recombinant protein could be a result of no or exceptionally low in 
vivo expression of the AaMLAP protein, resulting in a failure to induce an anti-AaMLAP 
antibody response in the mouse.  Alternative explanations could be poor immunogenicity 
of the AaMLAP protein, or failure of mouse anti-AaMLAP antibodies to recognize the 
non-glycosylated protein produced in from the bacterial expression system, or 
experimental error in the western blotting procedure.   
No reduction in mosquito survival was observed in mosquitoes that had fed on 
mice immunized (i.m.) with the AaMLAP-DNA immunization construct(2).  Post-
immune mouse serum did not detect protein corresponding to the expected molecular 
weight of AaMLAP in either the whole mosquito homogenate or in bacterial lysate that 
had been induced to express recombinant protein from the pBAD-AaMLAP plasmid.  
Again, given the lack of positive-control antiserum, we cannot conclude that anti-MLAP 
antibody was not generated in response to immunization. 
Using the pBAD/Thio-TOPO expression system, a recombinant protein 
containing a polyhistidine tag and V5 epitope was produced from the pBAD-AaMLAP 
plasmid.  When accounting for the polyhistidine tag and V5 epitope, the recombinant 
protein detected by the anti-V5-HRP antibody was the expected size of the AaMLAP 
protein.  Efforts to purify the protein yielded quantities that were too low to detect via 
colorimetric or spectrophotometric assays, thus mice were immunized with the 
polyacrylamide AaMLAP gel slurry.  In retrospect, a more appropriate control 
polyacrylamide gel slurry immunization would have been an excised SDS-PAGE gel 
strip from a non-transformed bacterial lysate, corresponding to the same molecular 
weight as the excised recombinant protein.   The polyacrylamide-BSA gel slurry did not 
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account for any bacterial antigens that were co-immunized with the recombinant protein, 
and it is possible that bacterial antigens in the mosquito midgut could have complexed 
with anti-E. coli antibodies ingested by the mosquito after feeding on immunized mice.  
Antibody-antigen complexes have been shown to cause blockages in the gut of the sheep 
blowfly larva, Lucillia cuprina, that result in death of the insect (Casu et al. 1997).  
Without the proper control in our experiments, we cannot rule out the possibility that the 
reduction in survival seen in mosquitoes that blood fed on the polyacrylamide-AaMLAP 
gel slurry immunized mice was not due to unintended immunological targeting of 
endosymbiotic bacteria in the mosquito midgut.    
We were unable to definitively demonstrate that any of the immunization 
regimens induced the production of AaMLAP antibodies in mice.  The lack of antibody 
production could be due to low immunogenicity of the AaMLAP immunization 
constructs, poor in vivo expression of AaMLAP from the pCDNA3.1(+) and AaMLAP 
SINV expression vectors, or error in the western blotting procedures used to probe for 
anti-AaMLAP antibody.  Ultimately, the experiments outlined above do not clearly 
define or eliminate the AaMLAP as a mosquitocidal antigen.  Given the lack of a positive 
control antiserum or purified AaMLAP protein, we decided to evaluate the GluCl anion 
channel as a potential mosquitocidal antigen. 
The GluCl anion channel is the target of the anthelmintic drug, ivermectin.  
Numerous studies have shown that when ivermectin is imbibed in a bloodmeal, mosquito 
survival is reduced (Pampiglioni et al. 1985, Iakubovich et al. 1989a, Tesh and Guzman 
1990, Cartel et al. 1991, Focks 1991, Focks et al. 1991, Mahmood et al. 1991, Gardner et 
al. 1993, Bockarie et al. 1999, Foley et al. 2000, Fritz et al. 2009, Kobylinski et al. 2010, 
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Sylla et al. 2010, Kobylinski et al. 2011).  We hypothesized that if Ae. aegypti 
mosquitoes imbibed a blood meal containing high-titer, GluCl antiserum, that survival of 
the mosquitoes would be reduced.  After feeding on a bloodmeal containing antiserum 
against the extracellular domain of the An. gambiae GluCl anion channel, we did not 
observe any reduction in mosquito survival.  Data from this experiment was not subjected 
to statistical analysis due to low feeding rates in the control-fed mosquitoes.  However, 
given that survival of mosquitoes after feeding on the GluCl antiserum was not affected, 
and that we had a limited supply of the antiserum, we did not repeat the experiment.  
Clearly one weakness in this experimental design is the use of heterologous antisera; 
however the extracellular domains of the An. gambiae and Ae. aegypti share a 90% amino 
acid identity.  One possible explanation for the lack of mortality observed in Ae. aegypti 
after blood feeding on the GluCl antiserum could be that antigenic variation between the 
anion channels of the two mosquitoes prevented the antiserum from binding to the Ae. 
aegypti GluCl receptor.  Another possible explanation is that the GluCl antiserum was 
raised against the extracellular domain of the GluCl anion channel, rather than the whole 
anion channel protein.  In Caenorhabditis elegans, ivermectin integrates between the 
transmembrane domains of the GluCl channel subunit proteins, thereby sterically opening 
the GluCl channel (Hibbs and Gouaux 2011).  It would be intriguing to determine if 
antibody raised against the transmembrane domains of the GluCl channel subunit 
proteins would mimic the effects of orally imbibed ivermectin on mosquito survival.  
Ultimately, we were not able to rule out the GluCl anion channel as a mosquitocidal 
antigen. 
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Mathematical modeling suggest that, if developed and deployed, mosquitocidal 
vaccines could be effective in decreasing the transmission of mosquito-borne pathogens 
such as DENV, CHIKV and YFV (Billingsley et al. 2008).   Ultimately, if mosquitocidal 
vaccines are ever to be used as a tool to decrease the transmission of mosquito-borne 
pathogens, specific mosquitocidal antigens must first be identified.  
  














Globally, human populations are routinely treated via mass drug administration 
(MDA) with anthelmintics for the control of numerous nematode parasites.  Ivermectin 
(IVM), diethylcarbamazine (DEC), and albendazole (ALB) are all currently administered 
via MDA for the control of onchocerciasis and lymphatic filariasis (Hotez 2007, Ottesen 
et al. 2008).  Pyrantel (PYL) is distributed for control of numerous human nematode 
infections, including hookworm, roundworm and whipworm infections (Reddy et al. 
2007).   Amid concerns over the emergence of drug-resistant parasites (Osei-
Atweneboana et al.) and reports of serious adverse events following MDA treatment of 
individuals co-infected with lymphatic filariasis and Loa loa (Kamgno et al. 2009), there 
has been a call for alternative MDA drugs and regimens (Bockarie and Deb 2010).  
Moxidectin (MOX) and selamectin (SEL) are anthelmintic drugs frequently used in 
veterinary medicine, but may eventually hold promise in augmenting current MDA 
regimens.  Clinical trials are underway to evaluate the efficacy of MOX for the control 
onchocerciasis in human populations (Siva 2009).     
There is considerable geographic overlap of locales treated by MDA and areas 
endemic for mosquito-borne diseases transmitted by Aedes aegypti.  Ae. aegypti is an 
anthropophilic mosquito and feeds frequently and nearly exclusively on humans (Scott et 
al. 2000b).  Given the considerable geographic overlap of human populations treated via 
MDA with the habitat of Ae. aegypti, it is reasonable to expect that Ae. aegypti will 
imbibe anthelmintic drugs and their metabolites circulating in human blood.  Models 
have clearly shown that even modest reductions in the daily probability of mosquito 
survival can dramatically reduce mosquito vectorial capacity (Black and Moore 2005, 
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Billingsley et al. 2008), and numerous studies have demonstrated that IVM is able to 
reduce the survival of adult mosquitoes (Pampiglioni et al. 1985, Iakubovich et al. 1989b, 
Tesh and Guzman 1990, Cartel et al. 1991, Jones et al. 1992, Gardner et al. 1993, 
Bockarie et al. 1999, Foley et al. 2000, Fritz et al. 2009, Sylla et al. 2010, Kobylinski 
2011).  In the field, MDA of IVM reduced the survival of field caught Anopheles 
mosquitoes (Bockarie et al. 1999, Sylla et al. 2010), and may also reduce malaria parasite 
transmission (Kobylinski 2011).   
While a large body of literature describing the effects of IVM on mosquitoes has 
been published, comparatively fewer reports evaluating the effects of other anthelmintic 
drugs on mosquitoes have been published.   At present, the effects of anthelmintics (other 
than IVM) have largely concentrated on Anopheles spp. (Kobylinski et al. 2010, Butters 
submitted), and there is one report that suggests MDA of DEC may reduce the survival of 
Ae. polynesiensis (Cartel et al. 1991).  With the exception of IVM, the effects of 
anthelmintic drugs have not yet been evaluated in Ae. aegypti. 
  The experiments described in this chapter employed an in vitro blood feeding 
assay to compare the effects of IVM, MOX, SEL, DEC, PYL, and albendazole sulfoxide 
(ALB SOx), the primary metabolite of ALB (Mathew 2007), on Ae. aegypti mosquitoes.  
The concentration of each drug required to kill 50% of adults (LC50(adult)) was calculated 
by feeding multiple concentrations of the drug to mosquitoes.  Drugs that induced adult 
mortality were further evaluated for their effect on mosquito fecundity and egg hatch rate.   
 





 Mosquitoes.  The Ae. aegypti Rexville D strain (RexD), origin Puerto Rico, was 
used in this study.  Mosquitoes were reared at 28⁰C ± 2⁰C, and 80% humidity under a 
photoperiod of 14:10 (L:D).  Larvae were raised in 28 L containers filled with 
approximately 15 L of tap water.  Larval density was maintained at 500-600 mosquito 
larvae per container in order to ensure uniform development and size.  Mosquito larvae 
were fed a diet of ground Tetramin® fish food mixed with ground mouse food.  Adult 
mosquitoes were provided with water and raisins as a sugar source ad libitum.  
 Drugs. Powdered formulations of IVM, DEC and PYL (as pyrantel pamoate) 
were purchased from Sigma-Aldrich (St. Louis, MO, USA).  A powdered formulation of 
ALB SOx was purchased from WITEGA (Berlin, Germany).  A powdered formulation of 
SEL was kindly provided by Pfizer, Inc. (Groton, CT, USA). All powders were dissolved 
in dimethylsulfoxide (DMSO) to a concentration of 10 mg/ml.  Multiple aliquots of each 
drug were stored, frozen, at -20⁰C.  A fresh aliquot was used for each blood feed.  
Moxidectin is not available in a powder form, and was thus purchased as the 10 mg/ml 
commercially available solution, Cydectin® (Fort Dodge Animal Health, Fort Dodge, IA, 
USA).  The Cydectin was maintained at 4⁰C in a light proof container, according to the 
manufacturer’s storage instructions.   
 In vitro blood feeds.  Human blood was used for all in vitro blood feeds.  Blood 
was drawn from a human volunteer into 3.2% sodium citrate blood collection tubes by a 
phlebotomist at the Colorado State University Health Network medical clinic in Fort 
Collins, Colorado.  Blood was drawn from the same volunteer for all of the experiments 
described, and was no more than one week post-draw at the time of the blood feed.   All 
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drugs were serially diluted into phosphate buffered saline (PBS) to a concentration 10 
times (10X) greater than the final desired concentration.  The 10X drug-PBS solutions 
were diluted 1:10 into blood to reach the final concentrations provided to mosquitoes.  
For all drug feeds, a drug-free control group was included.  At the time of blood feed, 
mosquitoes were 3-5 days post-emergence.  Twenty-four hours prior to the blood feed, 
adult mosquitoes were placed into 4 L plastic containers.  Mosquitoes were starved of 
sugar and water for 12 and three hours, respectively.  Glass membrane feeders (Lillie, 
Glass Blowers, Smyrna, GA, USA) were covered by securing hog sausage casing to the 
feeder with a rubber band, and were then heated and maintained at 37⁰C using a heated 
water circulator. Mosquitoes were allowed to feed for 30 minutes.  After the feed, 
mosquitoes were cold-anesthetized in a refrigerator, placed onto a glass Petri dish 
maintained on ice and sorted for the presence of a visible blood meal.  Only fully 
engorged mosquitoes were retained for survival analysis, fecundity and hatch rate studies. 
 LC50(adult) determination.  The concentration of drug required to kill 50% of 
adults (LC50(adult)) was determined by feeding each drug at multiple concentrations to 
mosquitoes, and all concentrations are reported in Figure 3.1.  Control mosquitoes, 
included in all experiments, were offered a blood meal containing 10% PBS.  The 
LC50(adult) for each drug was determined from three experimental replicates using a non-
linear mixed model with probit analysis (Proc probit, Proc nlmixed), (Kobylinski et al. 
2010).   
Estimation of fecundity.  The effects of IVM, MOX and SEL on the fecundity of 
Ae. aegypti were assessed by feeding each drug at multiple concentrations to mosquitoes 
(Figure 3.2). For IVM and SEL, control mosquitoes were fed on blood containing DMSO 
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which had been diluted in PBS.  The concentration of DMSO in the blood meal offered to 
control mosquitoes was equivalent to the concentration of DMSO contained the highest 
concentration of drug fed to experimental mosquitoes.  Moxidectin was provided as a 
suspension in an unknown carrier, and control mosquitoes were fed on blood containing 
PBS only.  Following the blood feed, mosquitoes were sorted for the presence of a blood 
meal (as described above), and five mosquitoes for each concentration of each drug were 
placed into 500 ml containers. Control mosquitoes were included in all experiments, and 
were selected to be of similar body and blood meal size.  A 10 ml oviposition cup lined 
with a paper towel was filled with approximately 8 ml of water and placed into each 
container.  Containers were covered with organdy fabric, and mosquitoes had access to 
raisins as a sugar source.  Two days following the blood feed, surviving mosquitoes were 
counted and recorded.  Five days post-blood feed, mosquitoes were anesthetized using 
carbon dioxide, and the oviposition cup was removed.  Eggs laid on the water surface 
were collected by filtering the water through a coffee filter.  Eggs were allowed to dry 
inside of a plastic container covered with organdy fabric, which was maintained in the 
insectary for three days.  Eggs were counted using a stereoscopic dissecting microscope.  
The number of eggs laid per female mosquito was estimated by dividing the total number 
of eggs by the number of surviving mosquitoes at two days post-blood feed.  Eggs were 
then placed into plastic bags and maintained in the insectary for five additional days. The 
effects of PYL, ALB SOx and DEC on mosquito fecundity were not evaluated due to the 
complete failure of these drugs to cause mortality in adult mosquitoes (see below).   
Hatch rate determination.  The effect of a maternal blood meal containing IVM, 
MOX and SEL on the hatch rate of eggs was assessed by submerging a subset of 50-60 
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eggs (obtained as described above) in 500 ml of tap water.  To minimize error associated 
with installment hatching (Gillett et al. 1977), water was de-oxygenated by bubbling 
nitrogen gas into the hatch container for 10 minutes.  Hatch cups were maintained in the 
insectary and three days after hatching all larvae were counted.  The number of eggs that 
failed to hatch was calculated by subtracting the number of larvae counted from the 
number of eggs submerged in water.  The concentration of drug contained in a maternal 
blood meal that prevented 50% of eggs from hatching (LC50(hatch)) was estimated using 
the NLM described above.  
Statistical analysis. The effect of IVM, MOX and SEL on the fecundity of Ae. 
aegypti RexD mosquitoes was assessed using a one-way ANOVA, and the mean number 
of eggs laid at each of the concentrations of IVM fed to mosquitoes was compared with 
the corresponding control group.  The significance level was set at P < 0.05, and 
statistical analysis was carried out using PROC GLM and least squares means procedure 
(SAS version 9.2, SAS Institute, Cary, NC, USA). 
The effect of IVM, MOX and SEL on the egg hatch rate was assessed for each 
mosquito strain by comparing the hatch rate from each concentration to the 
corresponding control.   Data from all three replicates were pooled and then analyzed 
using Fisher’s Exact test using R (http://www.r-project.org/). 
Results. 
LC50(adult) determination.  Ivermectin, MOX and SEL all reduced the survival of 
adult Ae. aegypti.  No reduction in adult mosquito survival was seen at the concentrations 
tested for DEC, PYL, or ALB SOx (Figure 3.1).  The LC50(adult) estimates and 
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corresponding 95% fiducial limits are reported in Table 3.1. Ivermectin had the lowest 
LC50(adult), followed by SEL, and finally MOX.   
Fecundity of Ae. aegypti following a blood meal containing anthelmintic 
drugs.  A one-way ANOVA revealed that the fecundity of Ae. aegypti was significantly 
affected following ingestion of IVM in a blood meal (F =32.89; df = 7, 23; P < 0.001).  A 
significant reduction in the mean number of eggs laid was seen at 800, 400, 200, 100, 75 
and 50 ng/ml concentrations of IVM (Figure 3.2a).  At the concentrations tested, 
significant reductions in fecundity were not observed with SEL or MOX (Figure 3.2a-b).    
Hatch rate of Ae. aegypti following a blood meal containing anthelmintic 
drugs.  The hatch rate of eggs was reduced following a maternal blood meal containing 
IVM, MOX and SEL.  Hatch rates for each drug, by concentration, are reported in Figure 
3.3.  Maternal blood meals containing IVM at concentrations of 400, 200, 100, and 75 
ng/ml resulted in a complete failure of eggs to hatch, and at 50 and 35 ng/ml the hatch 
rate was significantly less than the corresponding PBS-DMSO control (Figure 3.3a).  
Maternal blood meals containing SEL at all concentrations tested significantly reduced 
the egg hatch rate when compared to the corresponding PBS-DMSO control (Figure 
3.3b).  Maternal blood meals containing MOX significantly reduced the egg hatch rate at 
all but the lowest concentration tested (Figure 3.3c).  The LC50(hatch) estimate for IVM was 
38.0 ng/ml (35.8, 39.9), (Table 3.1).  Due to the limited effects of the experimental drug 
concentrations on the hatch rates of eggs, accurate estimates of the LC50(hatch) for SEL and 











Figure 3.1. Percent survival of Ae. aegypti (RexD) mosquitoes following blood meals containing different anthelmintic drugs. (A) IVM     
(B) SEL (C) MOX (D) DEC (E) PYL  (F) ALB SOx. 
(A) (B) (C) 




Table 3.1. Effect of imbibed anthelmintic drugs on adult survival and hatch 
rate of Ae. aegypti 
 
Drug LC50(adult) 
95% fiducial limits 
n 
LC50(hatch) 




n = 1,669 
38.0  
(35.8, 39.9) 
n = 1,125 
SEL 5,958 
(4,464, 7,531) 




n = 820 
n.d.* 
DEC n.d. 
n = 906 
n.e. 
PYL n.d. 
n = 924 
n.e. 
ALB SOx n.d. 
n = 1,106 
n.e. 
n :the number of individuals used to estimate the LC50 
 
n.d.: value could not be determined due to no mortality observed at 
experimental concentrations, and * a high hatch rate in all experimental 
concentrations 
 






Figure 3.2. Fecundity of Ae. aegypti (RexD) mosquitoes following blood meals containing different anthelmintic drugs. (A) IVM   (B) SEL  
 






Figure 3.3. Percent hatch rate of Ae. aegypti (RexD) mosquito eggs following a maternal blood meals containing different anthelmintic drugs. 
(A) IVM (B) SEL (C) MOX.  Significant reductions, relative to control,  in the percentage of eggs hatched are denoted with an *.  
(A) (B) (C) 





 Three outcomes (adult survival, fecundity and hatch rate) were used to evaluate 
the susceptibility of Ae. aegypti RexD to different concentrations of six anthelmintic 
drugs, when administered through a blood meal.  With the exception of MOX and SEL, 
all of the drugs evaluated in this study are currently distributed world-wide via MDA for 
the control of human nematode parasites (Hotez 2007, Reddy et al. 2007, Ottesen et al. 
2008).  Moxidectin, was included in this study, as it is currently being evaluated as a drug 
that could be used in addition to IVM for the control of onchocerciasis (Siva 2009).   
Selamectin, although only licensed for veterinary use can be applied topically for the 
control of endo and ecto parasites of companion animals (Bishop et al. 2000).  All MDA 
regimens are currently given orally, however, a topical application could be an attractive 
means of administering MDA, thus we also included SEL in our study.   
Others have reported on the effects of IVM on Ae. aegypti (Pampiglioni et al. 
1985, Tesh and Guzman 1990, Mahmood et al. 1991, Focks et al. 1995, Kobylinski et al. 
2010), but this is the first study to comparatively evaluate the efficacy of multiple 
anthelmintics in Ae. aegypti. The in vitro feeding strategy employed in this study allowed 
for consistent administration of the different anthelmintic drugs, thus allowing for direct 
comparisons of the effect of the drugs on adult survivorship, mosquito fecundity and 
hatch rate.  Of all the drugs tested, only the macrocyclic lactones (IVM and SEL) and the 
closely related milbemycin, MOX, significantly affected the survival of Ae. aegypti when 
imbibed in a blood meal.   
 In light of the recent clinical trials of MOX for the control of onchocerciasis, we 




The LC50(adult)  of MOX was 11,277 ng/ml, which is approximately 38 times higher than 
the mean maximal serum concentration of MOX (296 ng/ml) in human volunteers 
following a 36 mg, orally ingested dose (Cotreau et al. 2003).  These findings, coupled 
with the observation of adverse side effects at high doses indicate that MOX is unlikely 
to be effective in controlling pathogens transmitted by Ae. aegypti.    Selamectin has not 
yet been evaluated for tolerability or pharmacokinetics in humans, however the LC50(adult) 
of SEL in Ae. aegypti RexD was 5,958 ng/ml.  Even if such serum concentrations could 
be safely reached in humans, it would likely require a prohibitively expensive dose.   
 Ivermectin, MOX and SEL are all thought to exhibit insecticidal activity by 
allosterically agonizing the glutamate-gated chloride (GluCl) anion channels.  Binding of 
the drug to the channel causes an increased permeability of the channel to chloride ions, 
ultimately leading to hyperpolarization of the nerve-cell membrane culminating in flaccid 
paralysis and death of the insect (Cleland 1996, Wolstenholme and Rogers 2005).  
Despite significant structural similarities (reviewed in Chapter 1) between IVM, MOX 
and SEL, the efficacy of the drugs in inducing adult mortality was exceptionally variable.   
The most significant structural difference between IVM, MOX and SEL is the substituent 
found at the 13-position in the macrolide ring.  Moxidectin has no substituent at the 13-
position, SEL has an oleandrosyloxy subunit and IVM has a bisoleandrosyloxy subunit. 
The crystal structure of IVM bound to the GluCl channel in Caenorhabditis elegans  
shows that IVM integrates between the transmembrane domains of the channel subunit 
proteins, thereby opening the channel (Hibbs and Gouaux 2011).  Given that all of these 
drugs are allosteric agonists of the GluCl receptor, one possible explanation for the large 




properties of the substituent at the 13-position in the macrolide ring.  If the substituent at 
the 13-position in the macrolide ring alters the interaction of a macrocyclic lactone with 
the GluCl channel transmembrane domains, then macrocyclic lactones will vary in their 
efficacy in inducing mortality because the degree to which the channel is opened depends 
on the size and chemical properties of the substituent.  Of IVM, MOX and SEL, IVM has 
the largest substituent followed by SEL and finally MOX, suggesting that the size of the 
substituent may play some role in the endectocide efficacy of the drug.  The research 
presented here highlights the importance of elucidating the mechanism for the variability 
between the different macrocyclic lactones and milbimycins in their efficacy. Such 
knowledge could assist in the development of novel and more potent endectocide 
compounds.   
 Diethylcarbamazine, PYL and ALB SOx had no effect on the survival of adult Ae. 
aegypti.  Albendazole sulfoxide, the primary metabolite of albendazole, disrupts 
microtubule assembly, and PYL is a nicotinic acetylcholine-gated receptor agonist 
(Martin 1997).  The precise mode of action for DEC remains unclear, however it is 
established that DEC requires components from the vertebrate host for successful 
elimination of microfiliarial parasites (Hawking et al. 1948, McGarry et al. 2005).  
Hawking et al., 1948 observed that microfilarial parasites were rapidly eliminated from 
cotton rats following in vivo treatment with DEC, however the microfilaria were not 
susceptible to the drug in vitro.   Further, the survival of Aedes polynesiensis was 
significantly reduced in response to feeding on human patients that had been treated with 
DEC (Cartel et al., 1991).  While we did not observe a reduction in Ae. aegypti survival 




therefore the question of whether Ae. aegypti would experience reduced survival after 
feeding directly on a DEC-treated human remains to be answered.  With the exception of 
Africa, DEC remains the primary treatment for lymphatic filariasis world-wide.  Clearly, 
the question of whether a blood meal from a patient treated with DEC can reduce the 
survival of Ae. aegypti should be further explored.   
 We also investigated the effect of sublethal concentrations of IVM, MOX and 
SEL on the fecundity and hatch rate of Ae. aegypti RexD.  Due to their lack of effect on 
adult survival, DEC, PYL and ALB SOx were not further evaluated.  Ivermectin 
significantly decreased the fecundity of mosquitoes that ingested different concentrations 
of the drug, and these data are consistent with the findings of other reports of IVM in Ae. 
aegypti (Tesh and Guzman 1990, Mahmood et al. 1991).  At the concentrations 
evaluated, MOX and SEL had no significant effect on the fecundity of Ae. aegypti. The 
hatch rate of Ae. aegypti RexD was significantly reduced following a maternal blood 
meal containing IVM, MOX and SEL.  While IVM has been shown to reduce the 
fecundity and hatch rate of eggs following a sublethal maternal blood meal (Tesh and 
Guzman 1990, Mahmood et al. 1991), this is the first report to show that of MOX and 
SEL, albeit at exorbitantly high concentrations, can reduce the hatch rate of eggs 
following a maternal blood meal containing the drugs.  Fritz et al. demonstrated that 
hatchability of Anopheles gambiae eggs was not affected following a blood meal from 
bulls injected with a 600 µg/kg dose of MOX (Fritz et al. 2009), and these observations 
are likely due to the fact that the concentration of MOX imbibed was not high enough to 
affect the hatch rate of eggs.  The LC50(hatch) of IVM was 38.0 ng/ml in the Ae. aegypti 




the limited lethality at the experimental concentrations.   Additional experiments to 
pinpoint the LC50(hatch) were not carried out as it is unlikely that these endectocides will be 
effective in reducing transmission of mosquito-borne diseases by Ae. aegypti.    
 Of all the drugs that reduced mosquito survivorship, IVM was the most potent.  
Interestingly, our estimates for the LC50(adult) and LC50(hatch) of IVM for the Ae. aegypti 
RexD (601.3 ng/ml and 38.0 ng/ml, respectively) strain are noticeably higher than those 
observed by Tesh and Guzman in the Ae. aegypti Rock strain (LC50(adult ) = 126 ng/ml, 
LC50(hatch) = 3.4 ng/ml).  Due to different experimental methods, our results cannot be 
directly compared, nonetheless, the large difference in the LC50 estimates is notable.  
Following ingestion of a MDA dose of IVM (150 µg/kg), the mean maximal 
concentration of IVM in human venous plasma is approximately 46 ng/ml.  While the  
LC50(adult) of IVM calculated in both strains is far greater than the serum concentrations 
expected in human plasma, the question of whether other strains of Ae. aegypti may be 








CHAPTER 4:   THE EFFECT OF IVERMECTIN IN SEVEN DIFFERENT STRAINS 
OF AEDES AEGYPTI (DIPTERA: CULICIDAE), AND ESTIMATION OF REALIZED 








In the last 30 years, a number of in vitro and in vivo studies have demonstrated 
that, when imbibed in a blood meal, ivermectin (IVM) causes a significant reduction in 
adult female mosquito survival and fecundity, and decreased egg hatch rate (Pampiglioni 
et al. 1985, Iakubovich et al. 1989a, Tesh and Guzman 1990, Cartel et al. 1991, Focks 
1991, Focks et al. 1991, Mahmood et al. 1991, Gardner et al. 1993, Bockarie et al. 1999, 
Foley et al. 2000, Fritz et al. 2009).  Ivermectin, a macrocyclic lactone, is a broad-
spectrum drug which is widely used for the treatment of a number of parasitic infections, 
including the control of onchocerciasis and lymphatic filariasis.  Mass drug 
administration (MDA) of IVM through the African Programme for Onchocerciasis 
Control and the Global Program for the Elimination of Lymphatic Filariasis distributes 
IVM to over 80 million people annually across the globe (Amazigo 2008, Ottesen et al. 
2008).  There is considerable geographic overlap of locales treated by MDA with IVM 
and areas endemic for mosquito-borne diseases such as malaria and dengue.  It has been 
proposed that in addition to controlling nematode infections, more frequent MDA could 
also be effective in controlling mosquito-borne diseases (Wilson 1993, Kobylinski et al. 
2010, Foy et al. 2011, Kobylinski et al. 2011). 
A number of reports illustrate that MDA of IVM is effective in reducing the 
survivorship of adult mosquitoes (Cartel 1991, Bockarie 1999, Sylla 2010).   Two field-
based studies have demonstrated that MDA using IVM is significantly associated with 
the reduction in survivorship of adult field-caught mosquitoes (Bockarie et al. 1999, Sylla 
et al. 2010).  Mathematical models have shown that even modest reductions in the daily 




mosquito-borne disease such as dengue and malaria (Garrett-Jones 1964, Billingsley et 
al. 2008, Sylla et al. 2010)  Further, MDA of IVM is effective in disrupting malaria 
parasite transmission (Kobylinski 2011).  
Despite a growing body of literature on the effects of IVM in mosquitoes, the 
variation in susceptibility to IVM among strains of a mosquito species has not been 
investigated, nor have insecticide resistant strains been evaluated for IVM cross-
resistance, or whether IVM resistance may develop in a mosquito following successive 
blood meals containing IVM.  Multiple laboratory strains of Aedes aegypti are available 
and easily maintained in the lab, thus we chose Ae. aegypti as a model to study the 
variation in susceptibility to IVM imbibed in a blood meal, and to attempt to select for 
IVM resistance.  To assess the variation in susceptibility to IVM, seven strains of Ae. 
aegypti, including three laboratory-selected permethrin resistant strains, were 
administered blood meals containing IVM through an artificial membrane feeding 
system.  The concentrations of IVM which affected adult survivorship, fecundity and 
hatch rate were evaluated and compared among all seven mosquito lines.  To assess the 
likelihood of the development for IVM resistance, a genetically diverse laboratory strain 
(GDLS) was constructed (Wise de Valdez et al., 2010) and subjected to three successive 
rounds of selection with IVM, and the realized heritability (h2) was calculated. 
Materials and Methods 
 Mosquitoes.  The Solidaridad (SLD) strain originated from Mexico was collected 
as previously described (Flores et al. 2006), and the Iquitos strain (IQT) originating from 
Iquitos, Peru were from a lab colony maintained by Dr. Amy Morrison.  The SLD and 




(SLD-PR and IQT-PR, respectively), as described elsewhere (Saavedra-Rodriguez 2011).   
The Isla Mujeres strain (IMU-PR), was collected from the field and exhibited high levels 
of pyrethroid and temephos resistance without laboratory selection (Saavedra-Rodriguez 
et al. 2008).    The genetically diverse laboratory strain (GDLS) was constructed as 
described (Wise de Valdez et al. 2010).  The standard laboratory reference strain, New 
Orleans (NO), was kindly provided by the Center for Disease Control and Prevention 
(CDC), Atlanta, GA, USA.  All of the mosquitoes were reared at 28⁰C ± 2⁰C, 80% 
humidity under a photoperiod of 14:10 (L:D).  Larvae were raised in 28 L containers 
filled with approximately 15 L of tap water.  Larval density was maintained at 500-600 
mosquito larvae per container in order to ensure uniform development and size.  
Mosquito larvae were fed a diet of ground Tetramin® fish food mixed with ground 
mouse food.  Adult mosquitoes were provided with water and raisins as a sugar source ad 
libitum. 
 Ivermectin. A powdered formulation of Ivermectin (IVM) was obtained from 
Sigma-Aldrich (St. Louis, MO, USA) and dissolved in dimethylsulfoxide (DMSO) to a 
concentration of 10 mg/ml.  Multiple aliquots were stored, frozen, at -20⁰C.  A fresh 
aliquot was used for each blood feed. 
 In vitro blood feeds.  Human blood was used for all in vitro blood feeds.  Blood 
was drawn from a human volunteer into 3.2% sodium citrate blood collection tubes by a 
phlebotomist at the Colorado State University Health Network Medical Clinic in Fort 
Collins, Colorado.  Blood was drawn from the same volunteer for all of the experiments 
described, and was no more than one week post-draw at the time of the blood feed.   




buffered saline (PBS) to a concentration 10 times greater than the final concentration 
desired, which was finally diluted 1:10 into blood to reach the final concentrations 
provided to mosquitoes.  Control mosquitoes were fed PBS containing a concentration of 
DMSO equivalent to the highest concentration fed to experimental mosquitoes.  At the 
time of blood feed, mosquitoes were 3-5 days post-emergence.  Twenty-four hours prior 
to the blood feed, adult mosquitoes were placed into 4 L plastic containers.  Mosquitoes 
were starved of sugar and water for 12 and three hours, respectively, prior to the blood 
feed.  Glass membrane feeders (Lillie, Glass Blowers, Smyrna, GA) were covered by 
securing hog sausage casing to the feeder with a rubber band, and then heated to 37⁰C 
with a heated water circulator. Mosquitoes were allowed to feed for 30 minutes.  After 
the feed, mosquitoes were cold-anesthetized in a refrigerator, placed onto a glass Petri 
dish maintained on ice and sorted for the presence of a blood meal.  Only fully engorged 
mosquitoes were retained for survival analysis, fecundity and embryo survival studies. 
 LC50(adult) determination.  The concentration of IVM required to kill 50% of 
adults (LC50(adult)) was determined by feeding the following concentrations of the drug to 
mosquitoes: 800, 400, 200, 100, 75, 50, 35 and 0 ng/ml.  For each of the mosquito strains, 
the LC50(adult) was determined from three experimental replicates using a non-linear mixed 
model with probit analysis (NLM) (Kobylinski et al. 2010).  For each mosquito strain, the 
fit of the model with the experimental data was checked by plotting cumulative mortality 
from all replicates against the experimental concentration, and overlaying the resulting 
curve with a plot of the probit mortality versus IVM concentration calculated from the 




Estimation of fecundity. A subset of five fully engorged females were reserved 
from each of the blood feeds.  Mosquitoes of similar body and blood meal size were 
placed into 500 ml ice cream containers.  A 10 ml oviposition cup lined with a paper 
towel was filled with approximately 8 ml of water and placed into each container.  Ice 
cream containers were covered with organdy fabric, and mosquitoes had access to raisins 
as a sugar source.   Two days following the blood feed, surviving mosquitoes were 
counted and recorded. Five days post-blood feed, mosquitoes were anesthetized using 
carbon dioxide, and the oviposition cup was removed.  Eggs laid on the water surface 
were collected by filtering the water through a coffee filter.  Eggs were allowed to dry 
inside of a plastic container covered with organdy fabric which was maintained in the 
insectary for three days.  Eggs were counted using a stereoscopic dissecting microscope.  
The number of eggs laid per female mosquito was estimated by dividing the total number 
of eggs by the number of surviving mosquitoes at two days post-blood feed.  Eggs were 
then placed into plastic bags and maintained in the insectary for five additional days to 
allow for larvae development. 
LC50(hatch) determination.  The ability of IVM in a maternal blood meal to 
prevent 50% of eggs from hatching (LC50(hatch)) was assessed by submerging a subset of 
50-60 eggs  from mosquitoes fed each different concentration of IVM in 500 ml of water.  
To minimize installment hatching (Gillett et al. 1977), water was de-oxygenated by 
bubbling nitrogen gas into the hatch container for 10 minutes.  Hatch cups were 
maintained in the insectary, and three days after hatching all larvae were counted.  The 
number of eggs that failed to hatch was calculated by subtracting the number of larvae 




strain was calculated using the NLM described above.  The fit of the NLM for each of the 
mosquito strains was checked as described above. 
Selection for resistance to IVM in the Ae. aegypti GDLS.   We did not select 
for IVM resistance in adult mosquitoes because concentrations of IVM that significantly 
reduce adult survival have been reported to result in drastic reductions in mosquito 
fecundity and hatch rate, and production of successive generations would not be possible.  
Thus, we chose to evaluate whether or not the LC25(hatch) of IVM would increase in 
response selection pressure applied during three successive generations.  Due to a limited 
number of eggs and the high variation in hatch rate observed between individual 
replicates, the median LC25(hatch) value of the IQT, SLD and NO strains (48 ng/ml) was 
used for the initial round of selection.   
Three successive rounds of selection with IVM were carried out.  First generation 
GDLS eggs were used as the progenitor strain (designated GDLS-P1).  The first IVM-
selected generation was designated GDLS-FIVM 1, followed by  GDLS-F
IVM 
2, and finally 
GDLS-FIVM 3.    To generate the GDLS-F
IVM 
1, approximately 2,000 GDLS-P eggs were 
hatched, reared to adults and then fed a blood meal containing IVM at a concentration of 
48 ng/ml.  Mosquitoes were sorted for the presence of a blood meal as described above.  
Fully engorged mosquitoes were placed into flight cages containing four 200 ml 
oviposition containers which were lined with a paper towel and filled with approximately 
180 ml of tap water.  The GDLS-FIVM 1 eggs were collected five days after the blood 
feed, placed into a covered container maintained in the insectary, and allowed to dry for 
seven days.  A subset of GDLS-FIVM 1 eggs were then hatched, reared to adults and used 




LC50(hatch) as described above.  After the LC25(hatch) for the GDLS-F
IVM
1 was determined, 
the remainder of GDLS-FIVM 1 eggs were then counted and submerged in approximately 
500 ml of tap water.  Water was de-oxygenated as described in the previous section.  
Three days after hatching, all larvae were counted.  The proportion of viable eggs was 
calculated by dividing the total number of larvae counted by the total number of eggs 
submerged.   The resulting GDLS-FIVM 1 larvae were then reared to adults and fed a blood 
meal containing a concentration of IVM equivalent to the corresponding LC25(hatch) 
estimate for the GDLS-FIVM1.  Mosquitoes were sorted for the presence of a blood meal 
and transferred to a flight cage, allowing for oviposition of the GDLS-FIVM2  generation.   
The LC25(hatch) of the GDLS-F
IVM
2 generation was then determined by bioassay, and the 
GDLS-FIVM 3 generation was produced according to the same procedure. Selection-free, 
generation-matched control groups were maintained by feeding mosquitoes blood meals 
containing PBS with DMSO added at a concentration equivalent to that of the IVM-
treated groups.  Selection free generations are denoted as GDLS-FPBS 1, followed by 
GDLS-FPBS 2, and finally GDLS-F
PBS 
3.  
Estimation of realized heritability.  To estimate the additive genetic variance for 
development of IVM resistance in the GDLS mosquitoes, the realized heritability (h2) 
was estimated according to the methods described by Falconer and Mackay (Falconer 
1996).  Realized heritability h2 is estimated as the slope of a linear regression of the 
cumulative response to selection across generations on cumulative selection differential, 
and is given by the equation h2 = R/S  (where R is the cumulative response to selection 
and S is the cumulative selection differential).  The cumulative response to selection (R) 




the three successive generations.  The selection differential for each generation, denoted 
(R’) was estimated as 
R’ = [ln(generation LC25(hatch)) – ln(initial LC25(hatch))] 
where the generation LC25(hatch) is the LC25(hatch) at each generation following selection, 
and the initial LC25(hatch) is the LC25(hatch) of the parental generation prior to initiating 
selection.  The cumulative selection (S) differential was calculated by summing the 
estimated selection differential at each generation over the successive generations 
(denoted S’.)   The selection differential for each generation (S’) was estimated as 
 S’ = σi    
where i is the intensity of selection and σ is the standardized phenotypic variation. Values 
for the intensity of selection (i) corresponding to the proportion of survivors at each 
generation were obtained from Falconer and Mackay (Appendix A).  Values for the 
standardized phenotypic variation at each generation (σ) were estimated as 
 σ = 1/slope from the regression analysis 
where the slope from the regression analysis corresponds to the slope of the regression 
line from the NLM used to calculate the LC25(hatch) at each generation. 
Statistical analysis. The LC50(adult) and LC50(hatch) estimates were compared among 
experimental replicates.  Data from all seven strains was compared using a one-way 
ANOVA followed by multiple pairwise comparisons. Statistical analysis was carried out 




Resistance ratios for the LC50(adult) and LC50(hatch) were calculated relative to the 
susceptible NO strain. 
The effect of IVM on the fecundity for each mosquito line was assessed using a 
one-way ANOVA, and the mean number of eggs laid at each of the concentrations of 
IVM fed to mosquitoes was compared with the PBS-DMSO control group.  The 
significance level was set at P < 0.05, and statistical analysis was carried out using PROC 
GLM and least squares means procedure (SAS version 9.2, SAS Institute, Cary, NC).     
The effect of each IVM concentration on the egg hatch rate was assessed for each 
mosquito strain by comparing the hatch rate from each concentration to the 
corresponding PBS-DMSO control.  Data from all three replicates were pooled and then 
analyzed using a Fisher’s Exact Test (http://www.r-project.org/).  
   
Results 
Adult LC50 determination.  The LC50(adult) estimates and the corresponding 95% 
fiducial limits are reported in Table 4.1 and depicted in Figure 4.1.  Ivermectin reduced 
the survivorship of all strains of adult Ae. aegypti mosquitoes.  Calculated LC50(adult) IVM 
estimates across all mosquito lines ranged from 187 ng/ml to 576 ng/ml.  The LC50(adult) 
estimates of IVM for the IMU-PR, IQT-PR and SLD-PR strains differed significantly 
from the NO standard reference strain (P < 0.05)  The SLD and IQT strains did not differ 
from the NO standard reference strain (P > 0.05).  The GDLS did not differ significantly 
from any of the other mosquito strains.   Pairwise comparisons of strains IQT-PR and 




LC50(adult) estimates. The fit of the NLM for the LC50(adult) estimates for each mosquito 
strain is presented in Figure 4.2. 
Effect of IVM on hatch rate.  The LC50(hatch) estimates and the corresponding 
95% fiducial limits are reported in Table 4.1, and depicted in Figure 4.3.  The hatch rate 
of eggs from all mosquito strains was reduced following a maternal blood meal 
containing IVM.  Calculated LC50(hatch) IVM estimates across all mosquito lines ranged 
from 43 ng/ml to 334 ng/ml.    Hatch rates for each concentration of IVM recorded by 
mosquito strain are presented in Table 4.2.  The IMU-PR mosquito strain was the only 
strain that differed significantly from the susceptible NO strain.   Pairwise comparisons of 
strains IQT-PR and SLD-PR with their respective selection-free strains did not reveal 
significant differences.  The fit of the NLM for the LC50(hatch) estimates for each mosquito 
strain is presented in Fig 4.4.
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95 % fiducial 





95 % fiducial 
limits RR* Slope ± SE 
Intercept ± 
SE 
IMU-PR 576 (458.80, 722.96) 3.08 6.19 ± 0.48 -11.58 ± 3.07 334 (3.64, 645.12) 7.61 6.69 ± 0.87 -10.84 ±5.14 
SLD-PR 536 (402.11,822.64) 2.87 3.63 ± 0.31 -8.16 ± 1.89 60 (43.87, 76.83) 1.38 4.66 ± 0.32 -6.32 ± 1.39 
IQT-PR 487 (397.36,605.13) 2.60 5.29 ± 0.32 -10.3 ± 1.97 125 (79.96, 178.23) 2.84 2.44 ± 0.16 -4.28 ± 0.84 
GDLS 355 (297.04, 424.66) 1.90 4.06 ± 0.18 -8.21 ± 1.04 110 (75.65, 156.59) 2.52 2.66 ± 0.17 -4.59 ± 0.86 
IQT 284 (242.93, 331.32) 1.52 4.31 ± 0.17 -8.28 ± 0.99 75 (57.28, 92.43) 1.72 2.23 ± 0.17 -4.59 ± 0.86 
SLD 284 (242.03, 333.89) 1.52 4.10 ± 0.15 -7.9 ± 0.8 52 (40.44, 68.54) 1.20 10.18 ± 0.55 -9.21 ± 2.27 
NO 187 (162.79, 215.75) – 5.10 ± 0.15 -8.5 ± 0.81 43 (34.80, 50.95) – 10.49 ± 0.43 -8.91 ± 1.73 
* with respect to NO 
  
 





















Numbers correspond to the percentage of larvae hatching from eggs ± SEM.  Numbers denoted in bold font correspond with  
an overall significant reduction in hatch rate are denoted in bold font (Chi-square test for significance P<0.05). 
–  denotes a conc. where no mosquitoes survived to lay eggs




Conc. of ivermectin fed to female mosquito, ng/ml 
800 400 200 100 75 50 35 PBS-DMSO 
IMU-PR 4.2 ± 4.2 34.0 ± 31.1 77.0 ± 9.0 83.0 ± 9.4 98.0 ± 2.0 78.5 ± 14.8 92.7 ± 3.4 95.3 ± 2.7 
SLD-PR 0 1.7 ± 1.7 0 16.6 ± 8.9 47.2 ± 9.6 55.1 ± 10.6 76.7 ± 11.8 95.3 ± 2.7 
IQT-PR 0 6.1 ± 4.0 43.6 ± 14.0 68.5 ± 1.5 58.3 ±13.0 70.3 ± 8.7 76.1 ± 4.5 94.6 ± 2.8 
GDLS 0 16.7 ± 11.2 22.7 ± 16.2 39.2 ± 12.4 70.3 ± 13.9 80.1 ± 4.2 81.2 ± 4.2 96.0 ± 4.0 
IQT – 0.7 ± 0.7 0 34.7 ± 19.1 44.9 ± 5.1 81.0 ± 4.2 82.2 ± 10.2 96.8 ± 3.2 
SLD – 0 0 16.3 ± 16.3 12.6 ± 0.7 37.3 ± 19.3 93.9 ± 3.0 98.7 ± 1.3 
NO – – 0 12 ± 7.6 32.7 ± 16.5 32.7 ± 16.5 55.2 ± 1.7 82.5 ± 1.3 
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Figure 4.1: Comparison of LC50(adult)  for IVM between seven strains of Ae. aegypti.  
Error bars indicate experiment-wise standard error of the mean LC50  value of three 
replicate experiments.   Strains that did not differ significantly in the LC50(hatch) for IVM 








   
 
Figure 4.2: Fit of NLM to calculate 
LC50(adult) estimates for orally ingested IVM 
in seven strains of Ae. aegypti. A plot of 
the observed mortality versus the IVM 
concentration imbibed by mosquitoes was 
overlaid with a plot of the probit mortality 
versus predicted IVM concentration from 
the NLM.  (A) IMU-PR. (B) SLD-PR. (C) 




F. E.  
C.  D. 
A.  B. 
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Figure 4.3: Comparison of LC50(hatch)  for IVM between seven strains of Ae. aegypti.  
Error bars indicate experiment-wise standard error of the mean LC50  value from three 
replicate experiments.   Strains that did not differ significantly in the LC50(hatch) for IVM 










   
 
Figure 4.4: Fit of NLM to calculate 
LC50(hatch) estimates for orally ingested IVM 
in seven strains of Ae. aegypti. A plot of 
the observed mortality versus the IVM 
concentration imbibed by mosquitoes was 
overlaid with a plot of the probit mortality 
versus predicted IVM concentration from 
the NLM.  (A) IMU-PR. (B) SLD-PR. (C) 
IQT-PR. (D) GDLS. (E) IQT. (F) SLD. (G) 
NO.  
G.  
F. E.  
C.  D. 
A.  B. 
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Fecundity of Ae. aegypti mosquitoes following a blood meal containing IVM.  
A two-way ANOVA revealed that IVM concentration had a significant effect on the 
average number of eggs laid per female mosquito (F = 32.89; df =7, 112; P < 0.001), and 
that the mean number of eggs laid per female differed significantly among mosquito 
strains (F = 4.487; df = 6,112; P < 0.001).  There was no significant interaction effect 
between IVM concentration and mosquito strain (F=0.780, df = 42, 112, P =0.819).   
Because the average number of eggs laid per female differed significantly among 
mosquito strains, we analyzed the effects of IVM on the mean number of eggs produced 
per female for each mosquito strain separately (Table 4.3).  A significant reduction in the 
mean number of eggs laid by the IQT-PR and the SLD-PR strains was seen only at the 
800 and 400 ng/ml concentrations of IVM.  In the corresponding selection free strains, no 
mosquitoes survived to oviposit after feeding on IVM at a concentration of 800 ng/ml, 
and significant reductions in the mean number of eggs laid were seen following a blood 
meal containing 400 and 200 ng/ml of IVM (Table 4.3).  
Correlation between LC50 of permethrin and LC50(adult) of IVM.  We observed 
a significant correlation between the LC50 for permethrin (measured in µg/bottle) and the 
LC50 for IVM (Pearson’s product-moment correlation squared = 0.97, P = 0.002).  The 
LC50 estimates for each of the mosquito strains are published elsewhere (Saavedra-
Rodriguez et al. 2007, Saavedra-Rodriguez 2011).  A plot of the LC50 of permethrin 
versus the LC50(adult) for IVM is shown in Fig 4.5.  The GDLS was omitted from 
correlation analysis because the LC50 for permethrin was not available for this strain. 
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Conc. of ivermectin fed to female mosquito, ng/ml 
800 400 200 100 75 50 35 PBS-DMSO 
IMU-PR 11.2 ± 10.4 54.39  ± 33.6 60.5 ± 11.4 117.3 ± 22.1 120.1 ±11.5 111.7 ± 13.0 70.6 ± 8.5 128.1 ± 21.0 
SLD-PR 38 ± 38  30.8 ± 10.1 122.7 ± 48.4 105.6 ± 5.1 113.5 ± 3.2 133.1 ± 4.1 112.5 ± 4.7 122.4 ± 17.4 
IQT-PR 5.3 ± 5.3 34.6 ± 26.7 90.1 ± 13.0 91.0 ± 12.8 85.6 ± 28.1 113.9 ± 16.9 103.3 ± 12.0 125.0 ±6.5 
GDLS 1.8 ± 1.8 28.4 ± 14.3 53.4 ± 18.0 64.4 ± 12.1 83.6 ± 22.2 97.0 ± 11.6 92.4 ± 10.9 88.9 ± 5.1 
IQT – 7.9 ±7.9 18.8 ± 12.7 92.7 ± 30.0 81.3 ± 8.4 99.1 ± 12.1 90.9 ± 12.1 77.3 ± 21.1 
SLD – 9.3 ± 9.3 39.6 ± 28.3 81.0 ± 21.5 92.7 ± 14.0 134.7 ± 25.1 126.4 ± 26.7 118.7 ± 12.8 
NO – – 59.3 ± 26.7 65.2 ± 37.8 81.9 ± 17.3 98.9 ± 14.2 105.5 ± 7.2 118.4 ± 25.7 
Numbers correspond to the mean number of eggs ± SEM.  For each strain of mosquito, the mean number of eggs laid by 
mosquitoes at each concentration of IVM was compared to the corresponding control.  Significant reductions in fecundity are 
denoted in bold font (Chi-square test for significance (P < 0.05)). 
 –  denotes a conc. where no mosquitoes survived to lay eggs 
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Figure 4.5: Regression of LC50 of permethrin against the LC50(adult) of IVM in six strains 
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Correlation between LC50(adult) and LC50(hatch) of IVM.  The correlation 
observed between the LC50(adult) and LC50(hatch) of IVM was not significant (Pearson’s 
product-moment correlation = 0.70, P = 0.08).  
Estimation of realized heritability of resistance to IVM in the GDLS.  The 
LC25(hatch) for each generation of the IVM-selected GDLS and selection-free GDLS 
controls are reported in Table 4.4.   The LC25(hatch) of the GDLS-F
IVM
3 and the GDLS-
FPBS3  increased from 55 ng/ml to 69 ng/ml and 85 ng/ml, respectively (Table 4.5).   The 
cumulative response to selection (R) was -0.39 in the IVM-selected GDLS and was 0.89 
in the selection-free control.  The cumulated selection differential (S) was 0.83 in the 
IVM-selected GDLS and was 0.43 in the selection free controls.  Realized heritability 
(h2) estimates were estimated using the slope of the regression line of the cumulative 
response to selection versus the cumulated selection differential, and were -0.37 in the 
IVM-selected GDLS, and 2.08 for the selection free control (Table 4.5).  
    
   
 





























P  24  760/1000  55.48    10.6  894/1000  55 
F1  18.4  872/1069  101.96    14.7  891/1045  35 
F2  64.2  1372/3828  70.86    25  1289/1719  75 
F3  25  750/1125  69.41    20  237/1186  85 
a‐ 95% fiducial limits are not reported because estimates for the LC25(hatch) in generations F1 through F3 are from one 
experimental replicate. 
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Table 4.5: Estimation of realized heritability (h2) of IVM resistance in Ae. aegypti GDLS.  Parent generation to F3 























GDLS‐IVM  55.48  69.41  ‐0.39  0.67  0.57  2.66 ± 0.17  5.53 ± 0.17  0.18  0.83  ‐0.37 







Three outcomes (adult survival, fecundity and hatch rate) were used to evaluate 
the susceptibility of seven different lines of Ae. aegypti mosquitoes to different 
concentrations of IVM contained in a blood meal.  While we and others have reported on 
the effects of IVM on Ae. aegypti (Pampiglioni et al. 1985, Tesh and Guzman 1990, 
Mahmood et al. 1991, Focks et al. 1995, Kobylinski et al. 2010), this is the first analysis 
of variation in IVM susceptibility within a species.   This is also the first study to 
determine the LC50(adult) and LC50(hatch) of IVM in mosquitos with known insecticide 
resistance.   
We chose to use Ae. aegypti as a model in the present study due to our possession 
of multiple different mosquito strains that have been previously characterized, including 
the GDLS and three permethrin-resistant mosquito strains, two of which we also 
possessed their parent non-selected strains.  An advantage to using Ae. aegypti is that 
oogenesis is completed after one blood meal, whereas Anopheles gambiae has been 
shown to visually require more than one blood meal for completion of oogenesis 
(Fernandes and Briegel 2005).  Since effects of IVM on fecundity and hatch rate are 
temporary, and diminish after a second blood meal that does not contain IVM (Tesh and 
Guzman 1990), Ae aegypti is an attractive model for assessing the variability of the 
effects of IVM on mosquito fertility, egg development and viability.    
The in vitro feeding strategy employed in this study allowed for the consistent 
administration of varied concentrations of IVM to all of the mosquito strains, thus 
allowing for direct comparisons of the LC50(adult) and LC50(hatch) for  IVM among the 
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different strains.  Following oral ingestion of IVM in blood meal, we observed a large 
degree of variation in the LC50(adult) of IVM among strains.   
The LC50(adult)  estimates for all of the  laboratory-selected permethrin-resistant 
mosquito lines (IMU-PR, SLD-PR and IQT-PR) were significantly higher than the 
standard laboratory reference strain (NO).   A selection-free line of IMU could not be 
maintained in the laboratory; therefore a contrast between the IMU-PR strain and the 
corresponding selection-free strain could not be made.   However, the LC50(adult) for IVM 
in the SLD-PR and IQT-PR strains differed significantly from the corresponding 
selection-free strains, and the LC50 of permethrin was positively correlated with the 
LC50(adult) for IVM.  Collectively, these results indicate that a cross-resistance mechanism 
could be responsible for the increased tolerance to IVM by the IMU-PR, SLD-PR and 
IQT-PR Ae. aegypti mosquito strains.  These results were indeed quite surprising and 
unexpected.   
Ivermectin is an allosteric agonist of glutamate-gated chloride (GluCl) anion 
channels.  In parasitic worms, IVM binds the GluCl receptor causing an increased 
permeability to chloride ions, which then leads to hyperpolization of the nerve-cell 
membrane, leading to flaccid paralysis and death of the parasite (Cleland 1996, 
Wolstenholme and Rogers 2005).  However, they pyrethroids delay the normal closing of 
voltage-gated sodium channels of arthropods, resulting in depolarization of nerve-cell 
membranes ultimately leading to excessive neuroexcitation and death (Soderlund and 
Bloomquist 1989).  Given the disparate modes of action and target sites for these two 
compounds, cross-resistance is more likely due to metabolic mechanisms.   Permethrin-
induced cross-resistance to abamectin, a macrocyclic lactone differing from IVM only by 
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the presence of a double-bond, has been reported in house flies (Scott 1989, Geden et al. 
1992) and German cockroaches (Scott 1991).  In one study, permethrin-resistant Musca 
domestica were observed to have a 25-fold increased cross-resistance to abamectin that 
was temporarily suppressed by the mixed-function oxidase inhibitor, piperonyl butoxide 
(Scott 1989).   Reports of permethrin-induced cross-resistance to avermectin are 
conflicting.  Others have reported that permethrin-resistant house flies (Roush and Wright 
1986b) and permethrin-resistant German cockroaches (Cochran 1990) are fully 
susceptible to avermectin, and recently permethrin-resistant head lice were shown to be 
susceptible to IVM (Strycharz et al. 2008).  In all of these studies, avermectin or IVM 
was applied topically, which differs from our methods in which IVM was orally imbibed.      
While it is possible that the increased tolerance to IVM observed in any one of the 
permethrin-resistant Ae. aegypti mosquito strains is an artifact of laboratory-selection, it 
is interesting that adult mosquitoes of all three permethrin-resistant strains were 
approximately two-fold less susceptible to the effects of IVM than any of the permethrin-
susceptible lines.   Pyrethroid resistance in field populations of mosquitoes is well 
documented (Santolamazza et al. 2008, Garcia et al. 2009).  In light of the recent report 
and models that demonstrate MDA of IVM can disrupt the transmission of human 
malaria parasites (Sylla et al. 2010, Kobylinski 2011), the question of whether pyrethroid 
resistance can result in cross-resistance to IVM is clearly an area that needs to be further 
explored.    
The hatch rate of all mosquito strains was decreased following a maternal blood 
meal containing IVM.   These data are consistent with the findings of other reports of 
IVM in Ae. aegypti (Tesh and Guzman 1990, Mahmood et al. 1991), however the 
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LC50(hatch) of IVM for all of the mosquito strains we evaluated are notably higher than the 
previous reports. Tesh and Guzman (1990) reported a LC50(hatch) of 3.4 ng/ml using the 
Rock strain.   
With the exception of the IMU-PR strain, no significant differences among strains 
were observed with respect to the LC50(hatch) of IVM.  These results are strikingly different 
from those for the LC50(adult) estimates, where all permethrin-resistant strain estimates 
were significantly higher than standard susceptible strain.  In addition, there was no 
correlation between the LC50(adult)  and LC50(hatch) of IVM.  Collectively, these results 
suggest that IVM induces adult mortality and decreases the hatch rate of eggs through 
different mechanisms.   
Mahmood et al (1991) blood-fed Ae. aegypti mosquitoes on sublethal 
concentrations of IVM, and also observed a large decrease in hatch rate of the eggs from 
treated mosquitoes.  Many of the un-hatched eggs contained live larvae that failed to 
hatch despite multiple submersions in water (Mahmood et al. 1991).   In the same report, 
the authors propose that residual amounts of IVM may be deposited in the egg and 
prevent eclosion.    Such a mechanism could explain why we did not see a large 
variations in the LC50(hatch) of the mosquito strains.   Our experiments were not designed 
to elucidate the mechanism through which IVM interferes with egg hatching, but clearly 
this is an area that should be further explored.  
The maximal concentrations of IVM found in human venous plasma following a 
standard MDA dose of IVM (150 µg/kg) ranges from 9-75 ng/ml, with a mean maximal 
concentration of approximately 46 ng/ml (Elkassaby 1991).  The LC50(adult)  of IVM in Ae. 
aegypti reported here and elsewhere (Tesh and Guzman 1990, Kobylinski et al. 2010) are 
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far greater than the serum concentrations expected in humans following ingestion of the 
150 µg/kg dose of IVM typically used in MDA (Elkassaby 1991), thus it is unlikely that 
MDA administration of IVM will be effective in controlling diseases transmitted by Ae. 
aegypti.  Nonetheless, Ae. aegypti may prove to be a useful laboratory model for studying 
the mechanisms of IVM-induced pathology in the mosquito as well as potential 
mechanisms of resistance that could develop in the mosquito.   
In addition to characterizing the susceptibility of seven different Ae. aegypti 
mosquito lines to IVM, we also attempted to select for resistance to IVM in the GDLS.  
While several reports of IVM resistance in other organisms have been published (Rugg 
1998, Kane et al. 2000, Blackhall et al. 2003, Currie et al. 2004, Soutello et al. 2007, 
Klafke et al.), to the best of our knowledge there are no reports of IVM resistance in 
mosquitoes resulting from either field or laboratory selection.  Given the considerable 
promise that MDA of IVM has for reducing the transmission of mosquito-borne disease 
(Sylla et al. 2010, Foy 2011, Kobylinski 2011), we sought to investigate whether 
resistance to IVM could be selected for in a mosquito with a genetically diverse 
background.    
After three successive generations of selection, there was no evidence of a 
cumulative response to selection in the GDLS-IVM selected mosquitoes (r = -0.39).   
Interestingly, a strong cumulative response to selection (r= 0.89) was observed in the 
selection-free, generation-matched control GDLS population.  Prior to initiating the 
selection experiments, we anticipated that the LC25(hatch) estimates for IVM would 
fluctuate across generations, as seen in Table 4.4.  Such fluctuations are typical in 
artificial selection experiments, and the causes are presumably due to random genetic 
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drift, sampling error, and environmental variance (Falconer 1996).  The generation-
matched, selection-free control was included in this study to assess to what degree 
environmental variance contributed to the fluctuations in the LC25(hatch) between 
generations; however, due to the unexpected increase in the LC25(hatch) values in the non-
selected line, this was not possible.  It is important to note that both the GDLS-IVM 
selected population and the selection-free control population were each subject to the 
effects of random genetic drift, and random genetic drift is a likely explanation for the 
strong response to selection seen in the selection-free control.   
 Given the recent suggestion that IVM may serve as a potent tool in reducing the 
incidence of mosquito-borne disease, (Sylla et al. 2010, Foy 2011, Kobylinski 2011) we 
chose to use the Ae. aegypti GDLS as a model to study whether or not IVM resistance 
could rapidly develop in a genetically diverse mosquito population when IVM was 
repeatedly ingested through a blood meal.   While we did not see a response to selection 
to IVM in the GDLS-IVM selected mosquitoes, it is premature to conclude that resistance 
to IVM is unlikely to develop in Ae. aegypti in response to the drug being imbibed in a 
blood meal.  We only carried out our selection experiments for three generations.  
Assuming that an IVM-resistance allele or alleles are present in the GDLS, it is possible 
that a response to selection would have been observed in later generations if we had 
continued the selection process through successive generations, especially if resistance is 
conferred by a recessive allele. 
In summary, we found that in Ae. aegypti, adult survival following ingestion of 
IVM in a blood meal varies largely by mosquito strain, whereas the effect of a maternal 
blood meal on the ability of eggs to hatch varies among strains to a far lesser extent. We 
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did not see a response to selection for IVM resistance in the Ae. aegypti GDLS, however 
our results support that cross-resistance to IVM may develop in permethrin-resistant Ae. 
aegypti mosquitoes.  Clearly these are areas that necessitate additional research.  One 
possible approach to investigating the ability to laboratory select a mosquito strain for 
IVM resistance would be to cross an IVM-resistant strain (such as the IMU-PR) with an 
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CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS 
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The future of the control of mosquito-borne diseases will require the integration 
of novel methods to augment current vector control efforts. Two possibilities for novel 
control methods could include the development and deployment of anti-vector vaccines 
or the administration of anthelmintic drugs to human populations that are fed upon by 
vector mosquitoes.  
 The field of anti-mosquito immunity is still in its infancy, and has been largely 
ignored and unexplored.  The development and commercialization of two vaccines 
against the tick Boophilus microplus demonstrates that anti-vector immunity is not only 
possible, but is also highly effective in decreasing the burden of these ectoparasites in 
cattle (de la Fuente et al. 1999, Willadsen 1999, de la Fuente et al. 2008).  The 
experiments presented in this dissertation attempted to evaluate the Aedes aegypti 
mosquito lysosomal aspartic protease (AaMLAP) and a mosquito glutamate gated 
chloride anion channel as potential mosquitocidal antigens.  To evaluate AaMLAP as a 
potential antigen, we immunized mice with a number of immunization preparations, 
using a number of immunization regimens.  The recombinant cDNA immunization 
construct was chosen because of the ease of inserting the AaMLAP gene into the 
pCDNA3.1(+) immunization vector.  Further, the cDNA immunization strategy 
employed in the studies described here has been effective in eliciting consistent 
mosquitocidal responses, in mice, against Anopheles gambiae midgut cDNA (Foy et al. 
2003).  We were unable to induce a mosquitocidal response in mice through 
immunization with either the AaMLAP cDNA immunization construct or a recombinant 
AaMLAP-SINV expression vector, and possible reasons are discussed in Chapter 2.  
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Efforts to generate a purified source of recombinant AaMLAP protein were unsuccessful, 
and thus the mosquitocidal response elicited by mice immunized with the crude 
AaMLAP recombinant protein are difficult to interpret.  Without a source of purified 
AaMLAP, it was difficult to move forward in evaluating AaMLAP as a potential 
mosquitocidal antigen.  We therefore chose to investigate the effect of orally imbibed 
antiserum generated against the glutamate-gated chloride (GluCl) anion channel due to 
numerous studies which show oral ingestion of ivermectin (thought to be a GluCl 
agonist) causes a reduction in mosquito survival (Pampiglioni et al. 1985, Iakubovich et 
al. 1989a, Tesh and Guzman 1990, Cartel et al. 1991, Focks 1991, Focks et al. 1991, 
Mahmood et al. 1991, Gardner et al. 1993, Bockarie et al. 1999, Foley et al. 2000, Fritz et 
al. 2009, Kobylinski et al. 2010, Sylla et al. 2010, Kobylinski et al. 2011).  We did not 
see a reduction in mosquito survival after feeding on high titer GluCl antiserum and did 
not pursue the GluCl anion channel further as a mosquitocidal target for Ae. aegypti. 
 The difficulties encountered in evaluating the AaMLAP and GluCl anion channel 
as potential mosquitocidal antigens highlight the bottleneck in the discovery and 
development of anti-vector vaccines.  Ultimately, the key to the development of any anti-
vector vaccine is identification of specific target antigens.  Identifying the tick antigen, 
Bm86, the basis for the TickGARD and Gavac vaccines took ten years, requiring the 
fractionation of one kilogram of ticks, several rounds of immunizations and tick 
challenges (Willadsen 2004).  Such methods are painstakingly slow, and when one 
factors the cost of experimental animals, are exceptionally expensive.  If mosquitocidal 
vaccines are to someday become a reality, high throughput antigen screening methods 
must first be developed.     
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 Numerous studies have clearly demonstrated that when imbibed in a blood meal, 
certain anthelmintic drugs can elicit mosquitocidal responses (Pampiglioni et al. 1985, 
Iakubovich et al. 1989b, Tesh and Guzman 1990, Cartel et al. 1991, Focks et al. 1991, 
Mahmood et al. 1991, Jones et al. 1992, Gardner et al. 1993, Bockarie et al. 1999, Foley 
et al. 2000, Fritz et al. 2009, Chaccour et al. 2010, Sylla et al. 2010).   The research 
presented here provides a detailed and comparative evaluation of several anthelmintic 
drugs, including: ivermectin, moxidectin, selamectin, DEC, albendazole-sulfoxide and 
pyrantel for their ability to reduce survival of adult Ae. aegypti mosquitoes.  The results 
presented here and other published reports (Tesh and Guzman 1990, Focks et al. 1991, 
Mahmood et al. 1991) show that MDA of drugs frequently used for the control of 
nematode parasites are unlikely to impact the transmission of pathogens vectored by Ae. 
aegypti.  Nonetheless, our results highlight important questions that warrant further 
investigation.  
Of all the drugs tested, ivermectin was the most effective in reducing adult 
mosquito survival.  It is interesting that ivermectin, moxidectin and selamectin differed so 
greatly in their ability to reduce adult mosquito survival, as they are structurally similar 
compounds.  The mechanism for the difference in drug potency between these related 
compounds is unknown, but should be investigated.  An understanding of the underlying 
biochemical mechanism could be used to design more potent anthelmintic derivatives 
effective in targeting Ae. aegypti or other ivermectin-refractory mosquito genera such as 
Culex spp. mosquitoes (Tesh and Guzman 1990, Chandre and Hougard 1999).    
Although it is believed that ivermectin exerts insecticidal activity by agonizing 
the GluCl anion channel, a precise mechanism has not been proposed in any mosquito 
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species.    In analyzing the data presented here and in other published reports, it is clear 
that Anopheles  mosquitoes are far more susceptible to orally-imbibed ivermectin than 
Ae. aegypti.  The mechanism for the difference between these two mosquito species is not 
known, however the remarkable difference in susceptibility between the two genera 
should be further investigated.  Elucidating the mechanism responsible for the difference 
in ivermectin susceptibility between the genera could aid in engineering more potent 
endectocide drugs, but also promises considerable opportunity for increasing an 
understanding of the mechanism of action for ivermectin in mosquitoes as well as 
shedding light on many other aspects of mosquito physiology.   
Aedes aegypti may prove to be a useful laboratory model for investigating the 
effects of orally imbibed ivermectin over successive generations.  Recent field studies 
indicate that if administered on a monthly basis, ivermectin could have considerable 
potential for reducing malaria transmission by Anopheles  mosquitoes in the field (Sylla 
et al. 2010, Foy et al. 2011, Kobylinski et al. 2011).   There are many important questions 
to address, however, prior to implementing such an approach.  Questions such as whether 
such frequent administrations would select for ivermectin resistance in mosquitoes or 
nematode parasites currently treated with ivermectin must be first be answered.  For 
reasons already discussed, Ae. aegypti is exceptionally easy to rear and propagate in the 
laboratory.  The data presented in this dissertation argues for utilizing Ae. aegypti as a 
model to help begin investigating phenomena such as the existence of cross-resistance or 
development of resistance to ivermectin in a mosquito species. 
After three successive generations of selection with ivermectin, we did not see 
any evidence for the development of ivermectin resistance in Ae. aegypti.  These results 
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should not be interpreted to mean that resistance is unlikely to develop in field 
populations of mosquitoes if ivermectin were to be administered to human populations 
more frequently.  We and others have shown that ivermectin imbibed by mosquitoes in a 
blood meal not only affects adult survival, but also affects the fecundity, hatch rate and 
larval survival (Focks et al. 1991, Mahmood et al. 1991, Gardner et al. 1993, Fritz et al. 
2009).  Further, the effects of ivermectin on hatch rate and larval survival appear to occur 
at exceptionally low concentrations.  In field studies, a single MDA dose of ivermectin 
decreased adult Anopheles  mosquito survival for six days after administration (Sylla et 
al. 2010).  Sub-lethal effects of ivermectin MDA on fecundity, egg hatch rate and 
offspring survival could potentially extend for a greater period of time, thereby exerting 
selection pressure at all stages of the mosquito life cycle, with the exception being on the 
adult male mosquito.  Currently, ivermectin MDA is administered once or twice yearly in 
regions throughout the tropics and subtropics for the control and treatment of 
onchocerciasis and lymphatic filariasis.  Given the short half life of ivermectin, the 
current regimen is unlikely to result in ivermectin resistance in mosquitoes biting on 
treated people; however, careful consideration and additional laboratory experimentation 
determining whether or not resistance to ivermectin can be selected for in mosquitoes, 
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